Search for a doctor

Ayalew Tefferi, M.D.

  1. Hematologist
  2. Internist
Request an Appointment

Publications

  1. Aperna F, Alsugair AK, Fathima S, Tefferi A, Gangat N. Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors. Haematologica. 2025 Apr 1; 110 (4):1034-1037 Epub 2024 Nov 28
    View PubMed
  2. Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, Foran J, Palmer J, Badar T, Patnaik MM, Reichard KK, He R, Zepeda Mendoza CJ, Shah M, Orazi A, Arber DA, Pardanani A, Vannucchi AM, Hiwase D, Gangat N, Guglielmelli P. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100 (4):552-560 Epub 2025 Jan 28
    View PubMed
  3. Iftikhar M, Rana M, Jadoon Y, Abdelmagid M, Reichard K, Mendoza CZ, Pardanani A, Tefferi A, Gangat N. Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases. Haematologica. 2025 Mar 27 [Epub ahead of print]
    View PubMed
  4. Abdelmagid M, Palmer JM, Al-Kali A, Hefazi M, Foran J, Begna KH, Yi CYA, Pardanani A, Gangat N, Tefferi A. Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials. Haematologica. 2025 Mar 20 [Epub ahead of print]
    View PubMed
  5. Polverelli N, Hernandez-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sanchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke VAM, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison CN, Hobbs GS, Jain T, Khoury JD, Kiladjian JJ, Kroger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 Mar 19 [Epub ahead of print]
    View PubMed
  6. Shah MV, Hung FRCPA, Baranwal A, Kutyna MM, Al-Kali A, Toop C, Greipp PT, Brown AL, Shah SN, Khanna S, Ladon D, Gannamani V, Chen D, Begna K, Price Z, Rud D, Litzow MR, Hogan WJ, Bardy PG, Badar T, Kumar S, Yeung DT, Patnaik MM, Foran JM, He R, Gangat N, Scott HS, Arana-Yi C, Alkhateeb HB, Mangaonkar AA, Thomas D, Hahn CN, Orazi A, Arber DA, Kok CH, Tefferi A, Hiwase DK. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Mar 14 [Epub ahead of print]
    View PubMed
  7. Baranwal A, Langer K, Gannamani V, Rud D, Cibich A, Saygin C, Nawas MT, Badar T, Kharfan-Dabaja MA, Ayala E, Roy V, Foran JM, Murthy HS, Iqbal M, Palmer JM, Sproat L, Chhabra S, Khera N, Hefazi M, Mangaonkar AA, Hogan WJ, Litzow MR, Alkhateeb HB, Tefferi A, Kok CH, Guru Murthy GS, Patel AA, Bajel A, Hiwase DK, Shah MV. Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Mar 14 [Epub ahead of print]
    View PubMed
  8. Fathima S, Abdelmagid M, Alsugair A, Begna KH, Al-Kali A, Mangaonkar AA, Pardanani AD, Patnaik MM, Zepeda Mendoza CJ, He R, Reichard KK, Badar T, Foran JM, Palmer J, Loscocco GG, Guglielmelli P, Vannucchi AM, Orazi A, Arber DA, Hiwase D, Shah MV, Gangat N, Tefferi A. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Mar 13 [Epub ahead of print]
    View PubMed
  9. Gangat N, Tefferi A. Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes. Am J Hematol. 2025 Mar 8 Epub 2025 Mar 08
    View PubMed
  10. Thiele J, Kvasnicka HM, Gianelli U, Arber DA, Tefferi A, Vannucchi AM, Barbui T, Orazi A. Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification. Blood Cancer J. 2025 Mar 4; 15 (1):31 Epub 2025 Mar 04
    View PubMed
  11. Sharma N, Loscocco GG, Gangat N, Guglielmelli P, Pardanani A, Vannucchi AM, Alkhateeb HB, Tefferi A, Ho VT. When and how to transplant in myelofibrosis - recent trends. Leuk Lymphoma. 2025 Mar; 66 (3):359-377 Epub 2024 Nov 14
    View PubMed
  12. Fathima S, Alsugair A, He R, Mangaonkar AA, Begna KH, Pardanani A, Zepeda Mendoza CJ, Reichard KK, Gangat N, Tefferi A. Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases. Blood Cancer J. 2025 Mar 1; 15 (1):28 Epub 2025 Mar 01
    View PubMed
  13. Johnson IM, Ilyas R, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A, Gangat N. Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia following Venetoclax plus Hypomethylating Agent Therapy. Haematologica. 2025 Feb 27 [Epub ahead of print]
    View PubMed
  14. Tefferi A, Gangat N, Loscocco GG, Guglielmelli P, Szuber N, Pardanani A, Orazi A, Barbui T, Vannucchi AM. Essential Thrombocythemia: A Review. JAMA. 2025 Feb 25; 333 (8):701-714
    View PubMed
  15. Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2025 Feb; 100 (2):260-271 Epub 2024 Dec 13
    View PubMed
  16. Badar T, Knutson KL, Foran J, Gangat N, Pavelko KD, Kaufmann SH, Litzow MR, Murthy H, Cogen D, Ushman M, Arsana A, Al-Kali A, Alkhateeb H, Tefferi A, Patnaik M, Shah M. T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia. Blood Adv. 2025 Jan 28; 9 (2):239-243
    View PubMed
  17. Alsugair A, Fathima S, Aperna F, Gangat N, Tefferi A. Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Haematologica. 2025 Jan 23 [Epub ahead of print]
    View PubMed
  18. Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, Csizmar CM, Gurney M, Lasho TL, Finke CM, Mangaonkar AA, Al-Kali A, Pardanani A, Reichard KK, He R, Gangat N, Patnaik MM. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. Am J Hematol. 2024 Dec; 99 (12):2321-2327 Epub 2024 Sept 27
    View PubMed
  19. Barbui T, Carobbio A, Ghirardi A, Fenili F, Finazzi MC, Castelli M, Vannucchi AM, Guglielmelli P, Rambaldi A, Gangat N, Tefferi A. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis. Blood Cancer J. 2024 Nov 6; 14 (1):195 Epub 2024 Nov 06
    View PubMed
  20. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience. Haematologica. 2024 Nov 1; 109 (11):3785-3789 Epub 2024 Nov 01
    View PubMed
  21. Barbui T, Ghirardi A, Carobbio A, De Stefano V, Rambaldi A, Tefferi A, Vannucchi AM. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J. 2024 Oct 25; 14 (1):188
    View PubMed
  22. Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Dohner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani PJ, Vannucchi AM, Barbui T. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 Oct 24; 144 (17):1813-1820
    View PubMed
  23. Baranwal A, Shah MV, Greipp P, Shi M, Reichard KK, Jevremovic D, Gangat N, Patnaik MM, Begna KH, Alkhateeb HB, Litzow MR, Hogan WJ, Tefferi A, Al-Kali A, Mangaonkar AA. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes. Br J Haematol 2024 Oct; 205 (4):1627-1631 Epub 2024 July 31
    View PubMed
  24. Katamesh B, Nanaa A, He R, Viswanatha D, Greipp PT, Bessonen K, Nguyen P, Jevremovic D, Yi CA, Foran J, Begna K, Gangat N, Mangaonkar A, Saliba AN, Patnaik MM, Hogan WJ, Litzow M, Tefferi A, Shah MV, Alkhateeb HB, Al-Kali A. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience. Ann Hematol 2024 Oct; 103 (10):4333-4336 Epub 2024 Aug 28
    View PubMed
  25. Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 2024 Oct 1; 109 (10):3419-3425 Epub 2024 Oct 01
    View PubMed
  26. Gangat N, Singh A, Ilyas R, Loscocco GG, Elliott M, Begna K, Pardanani A, Tefferi A. Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies. Am J Hematol. 2024 Oct; 99 (10):1862-1869 Epub 2024 June 12
    View PubMed
  27. Tessier S, He R, Greipp P, Viswanatha D, Bessonen K, Lasho T, Foran J, Arana-Yi C, Gangat N, Tefferi A, Shah M, Alkhateeb H, Liu S, Pardanani A, Patnaik M, Al-Kali A. Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2024 Sep 24; 8 (18):4807-4811
    View PubMed
  28. Gangat N, Reichard K, Orazi A, Tefferi A. Autoimmune myelofibrosis: A Mayo Clinic series of 22 patients. Br J Haematol. 2024 Sep; 205 (3):956-960 Epub 2024 May 02
    View PubMed
  29. Farrukh F, Abdelmagid M, Mangaonkar A, Patnaik M, Al-Kali A, Elliott MA, Begna KH, Hook CC, Hogan WJ, Pardanani A, Litzow MR, Ketterling RP, Gangat N, Arber DA, Orazi A, He R, Reichard K, Tefferi A. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 Aug 1; 109 (8):2525-2532 Epub 2024 Aug 01
    View PubMed
  30. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01
    View PubMed
  31. Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Am J Hematol. 2024 Jul; 99 (7):1360-1387 Epub 2024 Apr 21
    View PubMed
  32. Li M, Baranwal A, Gurney M, Shah SN, Al-Kali A, Alkhateeb H, Foran J, Arana Yi C, Ongie L, Chen D, Mangaonkar A, McCullough K, Tefferi A, Lasho T, Finke C, Patnaik MM, Shah MV. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Adv. 2024 Jun 25; 8 (12):3130-3139
    View PubMed
  33. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024 Jun; 99 (6):1142-1165 Epub 2024 Mar 07
    View PubMed
  34. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Jun 1; 109 (6):1779-1791 Epub 2024 June 01
    View PubMed
  35. Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kroger N, Gagelmann N, Talpaz M, Kantarjian H, Gale RP. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11 (5):e383-e389 Epub 2024 Apr 08
    View PubMed
  36. Gangat N, McPhail E, Reichard K, Orazi A, Pardanani A, Tefferi A. Incidental discovery of KIT-mutated mastocytoma in a colon polyp. Am J Hematol. 2024 May; 99 (5):973-974 Epub 2024 Jan 25
    View PubMed
  37. Gangat N, Bellam N, Reichard K, Tefferi A. Emergence of TP53 mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine. Haematologica. 2024 Apr 1; 109 (4):1306-1309 Epub 2024 Apr 01
    View PubMed
  38. Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204 (4):1243-1248 Epub 2023 Dec 11
    View PubMed
  39. Gangat N, Tefferi A. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A. Am J Hematol. 2024 Apr; 99 (4):515-518 Epub 2024 Feb 20
    View PubMed
  40. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 Apr; 99 (4):697-718 Epub 2024 Jan 25
    View PubMed
  41. Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04
    View PubMed
  42. Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Desilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. CALR mutation burden in essential thrombocythemia and disease outcome. Blood. 2024 Mar 28; 143 (13):1310-1314
    View PubMed
  43. Pardanani A, Reichard K, Tefferi A. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat. Br J Haematol. 2024 Feb; 204 (2):402-414 Epub 2023 Dec 06
    View PubMed
  44. Tefferi A, Pardanani A, Gangat N. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. Am J Hematol. 2024 Feb; 99 (2):300-308 Epub 2024 Jan 02
    View PubMed
  45. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  46. Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024 Jan 18; 14 (1):11
    View PubMed
  47. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
  48. Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Kelemen K, Orazi A, Chen D, Reichard KK. Mast cell cytomorphology and treatment outcome in mast cell leukemia. Am J Hematol 2024 Jan; 99 (1):E5-E8 Epub 2023 Sept 21
    View PubMed
  49. Tefferi A, Abdelmagid M, Al-Kali A, Patnaik M, Hogan WJ, Begna K, Gangat N, Orazi A, Chen D, Reichard KK, Pardanani A. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. Am J Hematol. 2024 Jan; 99 (1):21-27 Epub 2023 Sept 29
    View PubMed
  50. Pardanani A, Tefferi A, Al-Kali A, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Orazi A, Kelemen K, Reichard KK, Chen D. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome. Am J Hematol 2024 Jan; 99 (1):E1-E4 Epub 2023 Sept 09
    View PubMed
  51. Kantarjian H, Zeidan AM, Fathi AT, Stein E, Rajkumar V, Tefferi A. Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective. Mayo Clin Proc. 2024 Jan; 99 (1):15-21 Epub 2023 Dec 16
    View PubMed
  52. Kroger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024 Jan; 11 (1):e62-e74 Epub 2023 Dec 04
    View PubMed
  53. Barbui T, Carobbio A, Thiele J, Gangat N, Rumi E, Rambaldi A, Vannucchi AM, Tefferi A, IWG-MRT group. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. Blood Cancer J. 2023 Dec 15; 13 (1):187
    View PubMed
  54. Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, Hanson CA, Ketterling RP, De Stefano V, Carobbio A, Barbui T, Guglielmelli P, Gangat N, Vannucchi AM. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol. 2023 Dec; 98 (12):1829-1837 Epub 2023 Sept 04
    View PubMed
  55. Gangat N, Tefferi A. Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology. Nephrol Dial Transplant. 2023 Nov 30; 38 (12):2670-2672
    View PubMed
  56. Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023 Nov 1; 108 (11):3033-3043 Epub 2023 Nov 01
    View PubMed
  57. Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023 Nov 1; 108 (11):2919-2932 Epub 2023 Nov 01
    View PubMed
  58. Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023 Nov 1; 108 (11):3170-3174 Epub 2023 Nov 01
    View PubMed
  59. Kuipers RS, Kok L, Virmani R, Tefferi A. Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist. Neth Heart J. 2023 Oct; 31 (10):371-378 Epub 2023 Feb 09
    View PubMed
  60. Badar T, Vanegas YAM, Nanaa A, Foran JM, Al-Kali A, Mangaonkar A, Murthy H, Alkhateeb HB, Viswanatha D, He R, Shah M, Yi CA, Litzow MR, Gangat N, Tefferi A, Patnaik MM. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023 Sep 21; 13 (1):149 Epub 2023 Sept 21
    View PubMed
  61. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 Sep; 98 (9):1465-1487 Epub 2023 June 26
    View PubMed
  62. Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematologica 2023 Sep 1; 108 (9):2542-2545 Epub 2023 Sept 01
    View PubMed
  63. Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer J. 2023 Aug 11; 13 (1):122
    View PubMed
  64. Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, Arber DA, Tefferi A. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023 Aug; 98 (8):1286-1306 Epub 2023 June 07
    View PubMed
  65. Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia 2023 Aug; 37 (8):1753-1756 Epub 2023 July 08
    View PubMed
  66. Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023 Jul 18; 13 (1):108 Epub 2023 July 18
    View PubMed
  67. Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood Adv. 2023 Jun 27; 7 (12):2694-2698
    View PubMed
  68. Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 Jun; 29 (6):360.e1-360.e8 Epub 2023 Feb 09
    View PubMed
  69. Gangat N, Szuber N, Tefferi A. JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management. Am J Hematol. 2023 Jun; 98 (6):965-981 Epub 2023 Apr 03
    View PubMed
  70. Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, Reichard K, Ketterling R, Gangat N, Xie Z, Fernandez J, Chia N, Gaspar-Maia A, Binder M, Patnaik MM. Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. Leukemia 2023 Jun; 37 (6):1384-1387 Epub 2023 Mar 25
    View PubMed
  71. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 May; 98 (5):801-821 Epub 2023 Feb 06
    View PubMed
  72. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2023 Apr 25; 7 (8):1351-1355
    View PubMed
  73. Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. TP53 mutation variant allele frequency of >/=10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J. 2023 Apr 11; 13 (1):51
    View PubMed
  74. Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J 2023 Apr 10; 13 (1):49
    View PubMed
  75. Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Apr; 98 (4):681-689 Epub 2023 Jan 04
    View PubMed
  76. Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol 2023 Apr; 98 (4):E76-E79 Epub 2023 Feb 06
    View PubMed
  77. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023 Mar 2; 141 (9):1087-1091
    View PubMed
  78. Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, Tefferi A. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2023 Feb; 98 (2):282-289 Epub 2022 Nov 15
    View PubMed
  79. Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, Tefferi A. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023 Jan 4; 13 (1):3 Epub 2023 Jan 04
    View PubMed
  80. Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, Kvasnicka HM. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023 Jan; 482 (1):53-68 Epub 2022 Dec 29
    View PubMed
  81. Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 Jan; 98 (1):166-179 Epub 2022 Oct 14
    View PubMed
  82. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. Haematologica 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01
    View PubMed
  83. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. Ann Hematol 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04
    View PubMed
  84. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03
    View PubMed
  85. Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Dohner H, Falini B, Garcia-Manero G, Haferlach T, Hellstrom-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Sole F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 Nov 24; 140 (21):2228-2247
    View PubMed
  86. Reichard KK, Tefferi A, Abdelmagid M, Orazi A, Alexandres C, Haack J, Greipp PT. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J. 2022 Nov 2; 12 (11):147 Epub 2022 Nov 02
    View PubMed
  87. Singh A, Alkhateeb H, Pardanani A, He R, Orazi A, Tefferi A, Reichard KK. Mast cell sarcoma: 2 Mayo Clinic cases. Am J Hematol. 2022 Oct; 97 (10):1381-1383 Epub 2022 Mar 21
    View PubMed
  88. Gangat N, Bleeker J, Lynch D, Olteanu H, Letendre L, Tefferi A. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica. 2022 Oct 1; 107 (10):2523-2526 Epub 2022 Oct 01
    View PubMed
  89. Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01
    View PubMed
  90. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01
    View PubMed
  91. Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Comparison between GATA2 and DDX41-mutated myeloid neoplasms. Leuk Res 2022 Oct; 121:106931 Epub 2022 Aug 23
    View PubMed
  92. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Lowenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Dohner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15; 140 (11):1200-1228
    View PubMed
  93. Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022 Sep 13; 6 (17):5227-5231
    View PubMed
  94. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30
    View PubMed
  95. Gangat N, Szuber N, Jadoon Y, Farrukh F, Begna K, Elliott MA, Wolanskyj-Spinner AP, Hanson CA, Pardanani AD, De Stefano V, Barbui T, Vannucchi AM, Tefferi A. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Adv. 2022 Jul 12; 6 (13):3835-3839
    View PubMed
  96. Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J. 2022 Jul 8; 12 (7):106 Epub 2022 July 08
    View PubMed
  97. Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol 2022 Jun 1; 97 (6):E210-E214 Epub 2022 Mar 29
    View PubMed
  98. Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, Tefferi A, Mangaonkar A, Howard M, Gangat N, Al-Kali A, Ali NA, Padron E, Patnaik MM. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 2022 Jun; 36 (6):1693-1696 Epub 2022 Mar 29
    View PubMed
  99. Dalvin LA, Olsen TW, Bakri SJ, McCullough K, Tefferi A, Al-Kali A. Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy. Am J Ophthalmol Case Rep. 2022 Jun; 26:101554 Epub 2022 Apr 21
    View PubMed
  100. Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Dohner H, Tefferi A. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol. 2022 May; 97 (5):514-518 Epub 2022 Feb 25
    View PubMed
  101. Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01
    View PubMed
  102. Gangat N, Oliveira JL, Porter TR, Hoyer JD, Al-Kali A, Patnaik MM, Pardanani A, Tefferi A. Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: The Mayo Clinic experience. Haematologica. 2022 May 01; 107(5):1201-1204.
    View PubMed
  103. Singh A, Al-Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, Abdelmagid MG, Farrukh F, Reichard KK, Gangat N, Pardanani A, Tefferi A. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022 May; 97 (5):630-637 Epub 2022 Feb 22
    View PubMed
  104. Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj-Spinner AP, Mangaonkar A, He R, Pardanani A, Shah M, Ketterling RP, Tefferi A. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3". Blood Cancer J 2022 Apr 7; 12 (4):55 Epub 2022 Apr 07
    View PubMed
  105. Szuber N, Elliott M, Tefferi A. Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management. Am J Hematol. 2022 Apr; 97 (4):491-505 Epub 2022 Feb 09
    View PubMed
  106. Gangat N, Jadoon Y, Szuber N, Hanson CA, Wolanskyj-Spinner AP, Ketterling RP, Pardanani A, Tefferi A. Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer J. 2022 Mar 17; 12 (3):44
    View PubMed
  107. Tefferi A, Gangat N, Pardanani A, Crispino JD. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Res. 2022 Mar 1; 82 (5):749-763
    View PubMed
  108. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Mar 1; 97 (3):352-372 Epub 2022 Jan 27
    View PubMed
  109. Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, Ramundo F, Rossi E, Kanthi Y, Tefferi A, Barbui T. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022 Feb 10; 12 (2):28
    View PubMed
  110. Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb 1; 12 (2):26 Epub 2022 Feb 01
    View PubMed
  111. Tefferi A, Kittur J, Farrukh F, Begna KH, Patnaik MM, Al-Kali A, Elliott MA, Reichard KK, Gangat N, Pardanani A. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2022 Feb; 196 (4):975-983 Epub 2021 Nov 03
    View PubMed
  112. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J 2022 Jan 25; 12 (1):12
    View PubMed
  113. Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022 Jan 25; 6 (2):528-532
    View PubMed
  114. Begna KH, Kittur J, Gangat N, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer J. 2022 Jan 17; 12 (1):7
    View PubMed
  115. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 Jan 1; 97 (1):68-78 Epub 2021 Nov 09
    View PubMed
  116. Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood 2021 Dec 30; 138 (26):2886-2889
    View PubMed
  117. Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, Coltro G, Betti S, Maccari C, Ceglie S, Chiusolo P, Paoli C, Barbui T, Tefferi A, De Stefano V, Vannucchi AM. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021 Dec 11; 11 (12):199
    View PubMed
  118. Gangat N, Oliveira JL, Hoyer JD, Patnaik MM, Pardanani A, Tefferi A. High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. Am J Hematol. 2021 Dec 1; 96 (12):1647-1654 Epub 2021 Oct 19
    View PubMed
  119. Gangat N, Guglielmelli P, Betti S, Farrukh F, Carobbio A, Barbui T, Vannucchi AM, De Stefano V, Tefferi A. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021 Dec 1; 96 (12):1580-1586 Epub 2021 Sept 10
    View PubMed
  120. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021 Dec; 35 (12):3339-3351 Epub 2021 Sept 03
    View PubMed
  121. Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, Maccari C, Ramundo F, Jadoon Y, Gesullo F, Ceglie S, Paoli C, Pardanani A, De Stefano V, Tefferi A, Vannucchi AM. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. Am J Hematol. 2021 Nov 1; 96 (11):1472-1480 Epub 2021 Sept 06
    View PubMed
  122. Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj AP, Howard MT, Hanson CA, Ketterling RP, Pardanani AD, Tefferi A. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol. 2021 Nov; 195 (3):413-416 Epub 2021 Aug 03
    View PubMed
  123. Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021 Nov 1; 96 (11):1450-1460 Epub 2021 Aug 27
    View PubMed
  124. Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, Vannucchi A, Jurgutis M, Ribrag V, Rambaldi A, Koh LP, Rose S, Zhang J, Harrison C. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021 Oct; 195 (2):244-248 Epub 2021 July 30
    View PubMed
  125. St Martin EC, Ferrer A, Wudhikarn K, Mangaonkar A, Hogan W, Tefferi A, Gangat N, Lasho T, Altman JK, Godley LA, Patnaik MM. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol 2021 Sep 1; 96 (9):E327-E330 Epub 2021 June 04
    View PubMed
  126. Gangat N, Szuber N, Pardanani A, Tefferi A. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia. 2021 Aug; 35 (8):2166-2181 Epub 2021 May 21
    View PubMed
  127. Tefferi A. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat. Am J Hematol. 2021 Jul 1; 96 (7):761-763 Epub 2021 May 03
    View PubMed
  128. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021 Jul 1; 96 (7):781-789 Epub 2021 May 06
    View PubMed
  129. Nanaa A, Viswanatha D, Xie Z, Jevremovic D, Nguyen P, Salama ME, Greipp P, Bessonen K, Gangat N, Patnaik M, Pardanani A, Alkhateeb HB, Shah M, Hogan W, Tefferi A, Litzow M, He R, Al-Kali A. Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer J 2021 Jun 30; 11 (6):122 Epub 2021 June 30
    View PubMed
  130. Szuber N, Tefferi A. Current Management of Chronic Neutrophilic Leukemia. Curr Treat Options Oncol. 2021 Jun 7; 22 (7):59 Epub 2021 June 07
    View PubMed
  131. Marinaccio C, Suraneni P, Celik H, Volk A, Wen QJ, Ling T, Bulic M, Lasho T, Koche RP, Famulare CA, Farnoud N, Stein B, Schieber M, Gurbuxani S, Root DE, Younger ST, Hoffman R, Gangat N, Ntziachristos P, Chandel NS, Levine RL, Rampal RK, Challen GA, Tefferi A, Crispino JD. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 Jun; 11 (6):1398-1410 Epub 2021 Feb 12
    View PubMed
  132. Squillace DL, Checkel JL, Tefferi A, Kita H, Gleich GJ. Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. J Immunol Methods. 2021 Jun; 493:113015 Epub 2021 Mar 06
    View PubMed
  133. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021 Apr 27; 5 (8):2272-2278
    View PubMed
  134. Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ, RESUME trialists. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia 2021 Apr; 35 (4):1197-1202 Epub 2020 Aug 07
    View PubMed
  135. Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD, Gangat N, Mangaonkar AA, Ketterling RP, Tefferi A, Solary E, Patnaik MM. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J 2021 Mar 11; 11 (3):54
    View PubMed
  136. Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, Litzow MR, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04
    View PubMed
  137. Begna KH, Ali W, Naseema Gangat Gangat, Elliott MA, Al-Kali A, Litzow MR, Christopher Hook C, Wolanskyj-Spinner AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer J. 2021 Mar 2; 11 (3):46 Epub 2021 Mar 02
    View PubMed
  138. Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". Am J Hematol. 2021 Mar 1; 96 (3):379-394 Epub 2021 Jan 28
    View PubMed
  139. Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021 Mar 1; 96 (3):354-366 Epub 2020 Dec 28
    View PubMed
  140. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, Litzow M, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer J 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01
    View PubMed
  141. Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Khan S, Rodriguez V, Tefferi A, Patnaik MM. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 2021 Feb; 35 (2):644-649 Epub 2020 June 08
    View PubMed
  142. Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR. The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. Blood Lymphat Cancer. 2021; 11:1-9 Epub 2021 Jan 22
    View PubMed
  143. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021 Jan; 96 (1):145-162 Epub 2020 Dec 02
    View PubMed
  144. Gangat N, Morsia E, Foran JM, Palmer JM, Elliott MA, Tefferi A. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br J Haematol 2020 Dec; 191 (5):e120-e124 Epub 2020 Sept 18
    View PubMed
  145. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Dec; 95 (12):1599-1613 Epub 2020 Oct 23
    View PubMed
  146. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020 Dec; 95 (12):1511-1521 Epub 2020 Sept 16
    View PubMed
  147. Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv 2020 Nov 24; 4 (22):5716-5721
    View PubMed
  148. Gangat N, Tefferi A. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer J. 2020 Nov 23; 10 (11):122
    View PubMed
  149. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020 Nov 10; 4(21):5425-5430.
    View PubMed
  150. Carobbio A, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S, Rambaldi A, Finazzi MC, Thiele J, Vannucchi AM, Tefferi A, Barbui T. A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer J. 2020 Oct 14; 10 (10):100
    View PubMed
  151. Gangat N, Pardanani A, Tefferi A. Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. Am J Hematol. 2020 Oct; 95 (10):1224-1225 Epub 2020 July 18
    View PubMed
  152. Gangat N, Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol. 2020 Oct; 191 (2):152-170 Epub 2020 Mar 20
    View PubMed
  153. Taylor J, Mi X, North K, Binder M, Penson A, Lasho T, Knorr K, Haddadin M, Liu B, Pangallo J, Benbarche S, Wiseman D, Tefferi A, Halene S, Liang Y, Patnaik MM, Bradley RK, Abdel-Wahab O. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood. 2020 Sep 24; 136 (13):1477-1486
    View PubMed
  154. Saliba AN, Ferrer A, Gangat N, Pruthi RK, Tefferi A, Higgins A, Bezerra ED, Buglioni A, Salama ME, Klee EW, Pinto E Vairo F, Mangaonkar A, Majerus J, Chen D, Patnaik MM. Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. Br J Haematol 2020 Sep; 190 (5):e316-e320 Epub 2020 June 22
    View PubMed
  155. DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia 2020 Sep; 34 (9):2519-2524 Epub 2020 Feb 14
    View PubMed
  156. Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug 13; 136 (7):909-913
    View PubMed
  157. Coltro G, Rotunno G, Mannelli L, Mannarelli C, Fiaccabrino S, Romagnoli S, Bartalucci N, Ravenda E, Gelli E, Sant'Antonio E, Patnaik MM, Tefferi A, Vannucchi AM, Guglielmelli P. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Adv. 2020 Aug 11; 4 (15):3677-3687
    View PubMed
  158. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020 May; 34 (5):1407-1421 Epub 2019 Dec 13
    View PubMed
  159. Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020 Apr; 189 (2):291-302 Epub 2020 Jan 16
    View PubMed
  160. Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. Am J Hematol 2020 Apr; 95 (4):E86-E89 Epub 2020 Jan 23
    View PubMed
  161. Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020 Mar 10; 10 (3):36
    View PubMed
  162. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33(3):514.
    View PubMed
  163. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33 (3):334-343 Epub 2019 Aug 30
    View PubMed
  164. Barbui T, Thiele J, Ferrari A, Vannucchi AM, Tefferi A. The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer J. 2020 Feb 25; 10 (2):22
    View PubMed
  165. Szuber N, Elliott M, Tefferi A. Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 2020 Feb; 95 (2):212-224 Epub 2019 Dec 30
    View PubMed
  166. Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Am J Hematol. 2020 Feb; 95 (2):156-166 Epub 2019 Nov 29
    View PubMed
  167. Patnaik MM, Tefferi A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020 Jan; 95 (1):97-115
    View PubMed
  168. Tefferi A, Pardanani A. Essential Thrombocythemia. N Engl J Med. 2019 Nov 28; 381 (22):2135-2144
    View PubMed
  169. Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM. Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Am J Hematol 2019 Sep; 94 (9):E231-E234 Epub 2019 June 14
    View PubMed
  170. Pophali PA, Timm MM, Mangaonkar AA, Shi M, Shi M, Reichard K, Tefferi A, Pavelko K, Villasboas JC, Jevremovic D, Patnaik MM. Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. Blood Cancer J 2019 Aug 16; 9 (9):65
    View PubMed
  171. Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019 Aug 15; 25 (16):4898-4906 Epub 2019 May 06
    View PubMed
  172. Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, Begna KH, Elliott MA, Hogan WJ, Tefferi A, Litzow MR, Go RS. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clin Proc. 2019 Aug; 94 (8):1467-1474
    View PubMed
  173. Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS. Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clin Proc. 2019 Aug; 94 (8):1542-1550
    View PubMed
  174. Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019 Jul; 94 (7):767-779 Epub 2019 May 03
    View PubMed
  175. Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica 2019 Jun; 104 (6):e236-e239 Epub 2019 Jan 03
    View PubMed
  176. Tefferi A, Pardanani A. Mutations and prognosis in myeloproliferative neoplasms. Leuk Lymphoma 2019 May; 60 (5):1112-1113 Epub 2018 Nov 14
    View PubMed
  177. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". Am J Hematol. 2019 Apr; 94 (4):475-488 Epub 2019 Jan 24
    View PubMed
  178. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019 Apr; 94 (4):599-610 Epub 2019 Feb 26
    View PubMed
  179. Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. Leukemia. 2019 Mar; 33 (3):780-785 Epub 2018 Oct 12
    View PubMed
  180. Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. Am J Hematol. 2019 Mar; 94 (3):299-305 Epub 2018 Dec 05
    View PubMed
  181. Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019 Mar; 94 (3):286-290 Epub 2018 Dec 05
    View PubMed
  182. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37 (1):96-102 Epub 2018 Dec 05
    View PubMed
  183. Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019 Jan 25; 9 (2):12
    View PubMed
  184. Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Hook CC, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019 Jan; 94 (1):5-9 Epub 2018 Oct 17
    View PubMed
  185. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019 Jan; 94 (1):133-143 Epub 2018 Nov 09
    View PubMed
  186. Fu C, Wen QJ, Marinaccio C, Ling T, Chen W, Bulic M, Lasho T, Tefferi A, Crispino JD, Xu K. AKT activation is a feature of CALR mutant myeloproliferative neoplasms. Leukemia. 2019 Jan; 33 (1):271-274 Epub 2018 Aug 06
    View PubMed
  187. Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. Am J Hematol 2018 Dec; 93 (12):E401-E404 Epub 2018 Oct 17
    View PubMed
  188. Shenoy N, Mudireddy M, Vallapureddy R, Leung N, Pagliaro L, Witzig T, Ou FS, Ordog T, Cheville J, Patnaik M, Thompson RH, Tefferi A, Begna K. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Dec; 16 (6):e1117-e1122 Epub 2018 June 28
    View PubMed
  189. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Dec; 93 (12):1551-1560 Epub 2018 Oct 26
    View PubMed
  190. Shah S, Pardanani A, Elala YC, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Tefferi A. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. Am J Hematol. 2018 Dec; 93 (12):1461-1466 Epub 2018 Sept 26
    View PubMed
  191. Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018 Dec; 93 (12):1474-1484 Epub 2018 Sept 27
    View PubMed
  192. Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM. Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leuk Lymphoma 2018 Dec; 59 (12):2998-3001 Epub 2018 Mar 27
    View PubMed
  193. Fan N, Lavu S, Hanson CA, Tefferi A. Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. Blood Cancer J. 2018 Nov 19; 8 (12):119
    View PubMed
  194. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018 Nov 13; 2 (21):2964-2972
    View PubMed
  195. Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A. Mutations and karyotype predict treatment response in myelodysplastic syndromes. Am J Hematol. 2018 Nov; 93 (11):1420-1426 Epub 2018 Sept 30
    View PubMed
  196. Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM. Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. Am J Hematol. 2018 Nov; 93 (11):1347-1357 Epub 2018 Oct 05
    View PubMed
  197. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018 Nov; 32 (11):2512-2518 Epub 2018 Apr 25
    View PubMed
  198. Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia. 2018 Oct; 32 (10):2274-2278 Epub 2018 Feb 27
    View PubMed
  199. Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clin Proc. 2018 Oct; 93 (10):1363-1374 Epub 2018 June 14
    View PubMed
  200. Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD. Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Adv. 2018 Aug 14; 2 (15):1980-1984
    View PubMed
  201. Pardanani A, Tefferi A. How I treat myelofibrosis after failure of JAK inhibitors. Blood. 2018 Aug 2; 132 (5):492-500 Epub 2018 June 04
    View PubMed
  202. Elliott MA, Tefferi A. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. Am J Hematol. 2018 Aug; 93 (4):578-587
    View PubMed
  203. Patnaik MM, Rangit Vallapureddy Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia. 2018 Aug; 32 (8):1850-1856 Epub 2018 Apr 02
    View PubMed
  204. Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Myelofibrosis Treatment Algorithm 2018. Blood Cancer J. 2018 Jul 31; 8 (8):72 Epub 2018 July 31
    View PubMed
  205. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat Gangat, Pardanani A, Vannucchi AM. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Jul; 32 (7):1631-1642 Epub 2018 Mar 23
    View PubMed
  206. Patnaik MM, Ketterling RP, Tefferi A. FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. Leuk Lymphoma 2018 Jul; 59 (7):1520-1522 Epub 2018 Jan 31
    View PubMed
  207. Perez Botero J, Ho TP, Hogan WJ, Kenderian S, Gangat N, Tefferi A, Abraham RS, Nguyen P, Oliveira JL, He R, Chen D, Viswanatha D, Rodriguez V, Khan SP, Patnaik MM. Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. Br J Haematol. 2018 Jul; 182(1):141-145. Epub 2017 May 09.
    View PubMed
  208. Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol 2018 Jun 10; 36 (17):1769-1770 Epub 2018 Apr 30
    View PubMed
  209. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol. 2018 Jun; 93 (6):824-840
    View PubMed
  210. Oliveira JL, Coon LM, Frederick LA, Hein M, Swanson KC, Savedra ME, Porter TR, Patnaik MM, Tefferi A, Pardanani A, Grebe SK, Viswanatha DS, Hoyer JD. Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. Am J Hematol. 2018 May 23. [Epub ahead of print]
    View PubMed
  211. Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018 May; 32 (5):1254-1258 Epub 2018 Jan 30
    View PubMed
  212. Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018 May; 32 (5):1189-1199 Epub 2018 Feb 02
    View PubMed
  213. Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018 May; 93 (5):649-654 Epub 2018 Feb 24
    View PubMed
  214. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May; 32 (5):1057-1069 Epub 2018 Feb 27
    View PubMed
  215. Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. Am J Hematol. 2018 May; 93 (5):691-697 Epub 2018 Feb 24
    View PubMed
  216. Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 May; 32 (5):1200-1210 Epub 2018 Feb 02
    View PubMed
  217. Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia 2018 Apr; 32 (4):1035-1038 Epub 2017 Nov 16
    View PubMed
  218. Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018 Mar 7; 8 (3):29 Epub 2018 Mar 07
    View PubMed
  219. Szuber N, Tefferi A. Driver mutations in primary myelofibrosis and their implications. Curr Opin Hematol. 2018 Mar; 25 (2):129-135
    View PubMed
  220. Vannucchi AM, Guglielmelli P, Tefferi A. Polycythemia vera and essential thrombocythemia: algorithmic approach. Curr Opin Hematol. 2018 Mar; 25 (2):112-119
    View PubMed
  221. Tefferi A, Lasho TL, Finke C, Gangat N, Hanson CA, Ketterling RP, Pardanani A. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. Leukemia 2018 Mar; 32 (3):837-839 Epub 2017 Nov 01
    View PubMed
  222. Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018 Mar; 93 (3):348-355 Epub 2017 Dec 18
    View PubMed
  223. Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018 Feb 27; 2 (4):370-380
    View PubMed
  224. Szuber N, Tefferi A. Chronic neutrophilic leukemia: new science and new diagnostic criteria. Blood Cancer J. 2018 Feb 13; 8 (2):19
    View PubMed
  225. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9; 8 (2):15 Epub 2018 Feb 09
    View PubMed
  226. Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 Feb 1; 36 (4):310-318 Epub 2017 Dec 09
    View PubMed
  227. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018 Jan 10; 8 (1):2
    View PubMed
  228. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018 Jan 10; 8 (1):3
    View PubMed
  229. Bikhchandani M, Johnson R, Tuan B, Tefferi A. Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRalpha Mutation. Acta Haematol. 2018; 140 (2):67-70 Epub 2018 Sept 05
    View PubMed
  230. Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, Finke C, Al-Kali A, Gangat N, Tefferi A. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018 Jan; 93 (1):65-73 Epub 2017 Nov 03
    View PubMed
  231. Tefferi A, Hanson CA, Ketterling RP. Revisiting the need for bone marrow examination in chronic myeloid leukemia. Am J Hematol. 2018 Jan; 93 (1):5-7 Epub 2017 Nov 03
    View PubMed
  232. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017 Dec 27; 7 (12):662
    View PubMed
  233. Tefferi A, Saeed L, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017 Dec; 31 (12):2851-2852 Epub 2017 Aug 18
    View PubMed
  234. Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am J Hematol. 2017 Dec; 92 (12):1311-1317 Epub 2017 Oct 20
    View PubMed
  235. Tefferi A, Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Nagorney DM. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. Am J Hematol. 2017 Nov; 92 (11):1187-1192 Epub 2017 Aug 24
    View PubMed
  236. Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Am J Hematol. 2017 Nov; 92 (11):1193-1197 Epub 2017 Aug 28
    View PubMed
  237. Tefferi A, Vannucchi AM. Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clin Proc. 2017 Aug; 92 (8):1283-1290
    View PubMed
  238. Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N, Shi M, Tefferi A, Solary E, Reichard KK, Jevremovic D. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 2017 Jul 21; 7 (7):e584 Epub 2017 July 21
    View PubMed
  239. Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017 Jul; 92 (7):1118-1128
    View PubMed
  240. Gurney M, Patnaik MM, Hanson CA, Litzow MR, Al-Kali A, Ketterling RP, Tefferi A, Gangat N. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. Br J Haematol. 2017 Jul; 178 (1):57-60 Epub 2017 Apr 17
    View PubMed
  241. Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Monocytosis in polycythemia vera: Clinical and molecular correlates. Am J Hematol. 2017 Jul; 92: (7)640-645.
    View PubMed
  242. Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. Eur J Haematol. 2017 Jul; 99 (1):36-41 Epub 2017 May 05
    View PubMed
  243. Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, Hanson CA, Tefferi A, Patnaik MM. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2017 Jun; 58 (6):1488-1493 Epub 2016 Oct 14
    View PubMed
  244. Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, Ketterling RP, Gangat N, Tefferi A. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017 Jun; 92 (6):542-548 Epub 2017 Apr 29
    View PubMed
  245. Farhadfar N, Cerquozzi S, Hessenauer MR, Litzow MR, Hogan WJ, Letendre L, Patnaik MM, Tefferi A, Gangat N. Acute leukemia in pregnancy: a single institution experience with 23 patients. Leuk Lymphoma. 2017 May; 58 (5):1052-1060 Epub 2016 Aug 26
    View PubMed
  246. Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A. Diagnostic impact of the 2016 revised who criteria for polycythemia vera. Am J Hematol. 2017 May; 92 (5):417-419 Epub 2017 Mar 04
    View PubMed
  247. Mudireddy M, Barraco D, Hanson CA, Pardanani A, Gangat N, Tefferi A. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. Am J Hematol. 2017 May; 92: (5)454-459.
    View PubMed
  248. Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A. Liver function test abnormalities and their clinical relevance in primary myelofibrosis. Blood Cancer J 2017 Apr 21; 7 (4):e557
    View PubMed
  249. Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 03; 127: (4)1316-1320.
    View PubMed
  250. Sharma P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, Hashmi SK, Litzow MR, Hogan WJ, Gangat N, Elliott MA, Al-Kali A, Tefferi A, Patnaik MM. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk Lymphoma. 2017 Apr; 58 (4):872-881 Epub 2016 Aug 11
    View PubMed
  251. Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017 Apr; 31 (4):896-902 Epub 2016 Oct 24
    View PubMed
  252. Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017 Mar 31; 7 (3):e550
    View PubMed
  253. Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017 Mar 10; 7 (3):e538
    View PubMed
  254. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017 Mar; 92 (3):297-310
    View PubMed
  255. Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017 Jan; 92 (1):56-61 Epub 2016 Dec 07
    View PubMed
  256. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017 Jan; 92 (1):94-108
    View PubMed
  257. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients /692/499 /692/699/1541/1990/2331 article Blood Cancer Journal. 2017; 7 (12):35
  258. Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016 Dec 13; 1 (2):105-111 Epub 2016 Nov 30
    View PubMed
  259. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 Dec; 91 (12):1262-1271
    View PubMed
  260. Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, Pacilli A, Hanson CA, Pancrazzi A, Ketterling RP, Mannarelli C, Barraco D, Fanelli T, Pardanani A, Gangat N, Vannucchi AM. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016 Nov 29; 1 (1):21-30 Epub 2016 Nov 22
    View PubMed
  261. Perez Botero J, Chen D, He R, Viswanatha DS, Majerus JA, Coon LM, Nguyen PL, Reichard KK, Oliveira JL, Tefferi A, Gangat N, Pruthi RK, Patnaik MM. Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets. 2016 Nov; 27 (7):712-715 Epub 2016 Apr 28
    View PubMed
  262. Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016 Nov; 30 (6):453-459 Epub 2016 June 11
    View PubMed
  263. Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A. Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia 2016 Nov; 30 (11):2273-2275 Epub 2016 Aug 01
    View PubMed
  264. Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J 2016 Oct 21; 6 (10):e487
    View PubMed
  265. Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, Robertson KD, Hanson CA, Tefferi A. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016 Sep 23; 6 (9):e472 Epub 2016 Sept 23
    View PubMed
  266. Pardanani A, Lasho T, Wassie E, Finke C, Zblewski D, Hanson CA, Ketterling RP, Gangat N, Tefferi A. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia 2016 Sep; 30 (9):1924-6 Epub 2016 Apr 05
    View PubMed
  267. Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, Chen D, Hanson CA, Ketterling RP, Tefferi A. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016 Sep; 91 (9):888-93 Epub 2016 June 20
    View PubMed
  268. Tefferi A. Somatic JAK2 mutations and their tumor phenotypes. Blood 2016 Aug 11; 128 (6):748-9
    View PubMed
  269. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: molecularly contaminated, but not defined. Leuk Lymphoma 2016 Aug; 57 (8):1751-2 Epub 2016 Apr 11
    View PubMed
  270. Farhadfar N, Cerquozzi S, Patnaik M, Tefferi A. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review. J Oncol Pract. 2016 Jul; 12 (7):611-21
    View PubMed
  271. He R, Wiktor AE, Durnick DK, Kurtin PJ, Van Dyke DL, Tefferi A, Patnaik MS, Ketterling RP, Hanson CA. Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. Am J Clin Pathol. 2016 Jul; 146 (1):86-94 Epub 2016 June 27
    View PubMed
  272. Barraco D, Lasho TL, Gangat N, Finke C, Elala YC, Pardanani A, Tefferi A. Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. Blood Cancer J 2016 Jun 17; 6:e436 Epub 2016 June 17
    View PubMed
  273. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Myeloproliferative neoplasms: Morphology and clinical practice. Am J Hematol. 2016 Jun; 91 (4):430-3
    View PubMed
  274. Vaa BE, Tefferi A, Gangat N, Pardanani A, Lasho TL, Finke CM, Wolanskyj AP. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Ann Hematol. 2016 Jun; 95: (7)1185-9.
    View PubMed
  275. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016 Jun; 91 (4):390-4
    View PubMed
  276. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016 Jun; 91 (6):631-42
    View PubMed
  277. Begna K, Abdelatif A, Schwager S, Hanson C, Pardanani A, Tefferi A. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. Blood Cancer J 2016 May 27; 6:e427
    View PubMed
  278. Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016 May; 91 (5):492-8 Epub 2016 Apr 04
    View PubMed
  279. Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016 May; 91 (5):503-6 Epub 2016 Apr 04
    View PubMed
  280. Gangat N, Patnaik MM, Begna K, Al-Kali A, Litzow MR, Ketterling RP, Hanson CA, Pardanani AD, Tefferi A. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J 2016 Apr 8; 6:e414 Epub 2016 Apr 08
    View PubMed
  281. Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J 2016 Apr 8; 6:e415 Epub 2016 Apr 08
    View PubMed
  282. Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr; 30 (4):889-96 Epub 2015 Oct 07
    View PubMed
  283. Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Morice WG, Morice Ii WG, Brooks C, Grogg KL, Hanson CA, Tefferi A, Chen D. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. Leukemia. 2016 Apr; 30 (4):914-8 Epub 2015 Dec 18
    View PubMed
  284. Tefferi A, Al-Kali A, Begna KH, Patnaik MM, Lasho TL, Rizo A, Wan Y, Hanson CA. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J 2016 Mar 11; 6:e405
    View PubMed
  285. Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 2016 Mar; 91 (3):341-9 Epub 2016 Feb 09
    View PubMed
  286. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016 Feb 5; 6 (2):e393 Epub 2016 Feb 05
    View PubMed
  287. Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clin Proc. 2016 Feb; 91 (2):259-72
    View PubMed
  288. Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016 Jan 15; 6 (1):e385
    View PubMed
  289. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016 Jan; 91 (1):76-89
    View PubMed
  290. Cerquozzi S, Farhadfar N, Tefferi A. Treatment of Myelofibrosis: A Moving Target. Cancer J. 2016 Jan-Feb; 22: (1)51-61.
    View PubMed
  291. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016 Jan; 91 (1):50-8
    View PubMed
  292. Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21 (12):1473-80 Epub 2015 Nov 16
    View PubMed
  293. Gangat N, Patnaik MM, Begna K, Kourelis T, Al-Kali A, Elliott MA, Hogan WJ, Letendre L, Litzow MR, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani AD, Tefferi A. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. Mayo Clin Proc. 2015 Dec; 90 (12):1623-38 Epub 2015 Nov 03
    View PubMed
  294. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015 Nov 27; 5:e369
    View PubMed
  295. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015 Nov 13; 5:e366
    View PubMed
  296. Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov; 29 (11):2126-33 Epub 2015 Aug 21
    View PubMed
  297. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015 Sep 3; 373 (10):908-19
    View PubMed
  298. Tefferi A, Barbui T. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. Mayo Clin Proc. 2015 Sep; 90: (9)1283-93.
    View PubMed
  299. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015 Aug 14; 5:e337
    View PubMed
  300. Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015 Aug 7; 5:e335 Epub 2015 Aug 07
    View PubMed
  301. Tefferi A, Barbui T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. Am J Hematol. 2015 Aug; 90(8):683-5.
    View PubMed
  302. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1 (5):643-51
    View PubMed
  303. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333 Epub 2015 July 31
    View PubMed
  304. Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol. 2015 Jul; 90 (7):653-6
    View PubMed
  305. Pardanani A, Lasho T, Chen D, Kimlinger TK, Finke C, Zblewski D, Patnaik MM, Reichard KK, Rowinsky E, Hanson CA, Brooks C, Tefferi A. Aberrant expression of CD123 (interleukin-3 receptor-alpha) on neoplastic mast cells. Leukemia 2015 Jul; 29 (7):1605-8 Epub 2015 Feb 02
    View PubMed
  306. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015 Jun; 90 (6):549-59
    View PubMed
  307. Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015 May; 90(5):411-6. Epub 2015 Apr 01.
    View PubMed
  308. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, Tefferi A. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015 Apr; 169 (1):77-80 Epub 2014 Dec 15
    View PubMed
  309. Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol. 2015 Apr; 169 (1):71-6 Epub 2014 Dec 17
    View PubMed
  310. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015 Apr; 1 (1):97-105
    View PubMed
  311. Pardanani A, Tefferi A, Guglielmelli P, Bogani C, Bartalucci N, Rodriguez J, Extremera S, Perez I, Alfaro V, Vannucchi AM. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer J. 2015 Mar 13; 5:e286
    View PubMed
  312. Tefferi A, Elliott M, Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol. 2015 Mar; 22(2):171-6.
    View PubMed
  313. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Feb; 90 (2):162-73
    View PubMed
  314. Lasho TL, Finke CM, Zblewski D, Patnaik M, Ketterling RP, Chen D, Hanson CA, Tefferi A, Pardanani A. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J. 2015 Jan 23; 5:e275
    View PubMed
  315. Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015 Jan 2; 5:e270 Epub 2015 Jan 02
    View PubMed
  316. Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. Am J Hematol. 2015; 90(5):434-7.
    View PubMed
  317. Gangat N, Wassie EA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Passamonti F, Tefferi A. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015 Jan; 94(1):31-6. Epub 2014 Dec 4
    View PubMed
  318. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kroger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2015 Jan; 29 (1):20-6 Epub 2014 Aug 25
    View PubMed
  319. Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014 Dec 12; 4 (12):e268
    View PubMed
  320. Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP, Hanson CA, Pardanani A, Gangat N, Wolanskyj AP. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014 Dec; 28 (12):2300-3 Epub 2014 May 05
    View PubMed
  321. Pardanani A, Tefferi A. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis? Leuk Lymphoma. 2014 Dec; 55 (12):2706-11
    View PubMed
  322. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Solary E, Tefferi A, Patnaik MM. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014 Dec; 89: (12)1111-5.
    View PubMed
  323. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014 Nov; 28 (11):2206-12 Epub 2014 Apr 03
    View PubMed
  324. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct 16; 124 (16):2507-13; quiz 2615 Epub 2014 July 18
    View PubMed
  325. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014 Sep; 89(9):915-25.
    View PubMed
  326. Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014 Sep; 28 (9):1774-83 Epub 2014 Apr 04
    View PubMed
  327. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NC, Vannucchi AM, Tefferi A. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014 Sep; 28 (9):1804-10 Epub 2014 Feb 19
    View PubMed
  328. Chintakuntlawar AV, Finnes HD, Tefferi A, Pardanani A. Drug-drug interaction between bosutinib and warfarin. Leuk Lymphoma 2014 Sep; 55 (9):2213-4 Epub 2014 Jan 28
    View PubMed
  329. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014 Aug; 89(8):E121-4. Epub 2014 May 16.
    View PubMed
  330. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014 Jul; 28 (7):1407-13 Epub 2014 Jan 20
    View PubMed
  331. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, Belachew AA, Pancrazzi A, Wassie EA, Ketterling RP, Hanson CA, Pardanani A, Vannucchi AM. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014 Jul; 28 (7):1494-500 Epub 2014 Feb 05
    View PubMed
  332. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014 Jul; 28 (7):1472-7 Epub 2014 Jan 09
    View PubMed
  333. Elliott MA, Tefferi A. Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. Am J Hematol. 2014 Jun; 89(6):651-8.
    View PubMed
  334. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014 Jun; 28 (6):1191-5 Epub 2013 Dec 19
    View PubMed
  335. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014 May; 165 (3):273-86 Epub 2014 Jan 28
    View PubMed
  336. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 1; 36 (4):560-6 Epub 2014 Mar 14
    View PubMed
  337. Tiziana Storlazzi C, Pieri L, Paoli C, Daniele G, Lasho T, Tefferi A, Vannucchi AM. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. Am J Hematol. 2014 Apr; 89(4):438-42.
    View PubMed
  338. Elliott MA, Tefferi A. The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy. Curr Opin Hematol. 2014 Mar; 21(2):148-54.
    View PubMed
  339. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014 Mar; 28 (3):485-96 Epub 2013 Nov 13
    View PubMed
  340. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Mullauer L, Ruggeri M, Rambaldi A, Tefferi A. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014 Feb; 89(2):199-202.
    View PubMed
  341. Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014; 89(6):588-90.
    View PubMed
  342. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, Luigia Randi M, Betozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Mullauer L, Ruggeri M, Rambaldi A, Tefferi A. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014 Jan; 89(1):52-4. Epub 2013 Sep 19.
    View PubMed
  343. Taner T, Nagorney DM, Tefferi A, Habermann TM, Harmsen WS, Slettedahl SW, Donohue JH. Splenectomy for massive splenomegaly: long-term results and risks for mortality. Ann Surg. 2013 Dec; 258 (6):1034-9
    View PubMed
  344. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013 Nov; 88 (11):967-74
    View PubMed
  345. Pardanani A, Chen D, Abdelrahman RA, Reichard KK, Zblewski D, Wood AJ, McClure RF, Butterfield JH, Hanson CA, Tefferi A. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013 Oct; 27 (10):2091-4 Epub 2013 July 30
    View PubMed
  346. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013 Oct; 27(10):1953-8. Epub 2013 Mar 07.
    View PubMed
  347. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013 Sep; 27(9):1861-9. Epub 2013 Apr 26.
    View PubMed
  348. Lasho T, Johnson SH, Smith DI, Crispino JD, Pardanani A, Vasmatzis G, Tefferi A. Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. Am J Hematol. 2013 Sep; 88(9):741-6. Epub 2013 Aug 01.
    View PubMed
  349. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep; 27 (9):1874-81 Epub 2013 June 06
    View PubMed
  350. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013 Sep; 27 (9):1870-3 Epub 2013 Apr 22
    View PubMed
  351. Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90. Epub 2013 Jun 10.
    View PubMed
  352. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22; 122 (8):1395-8 Epub 2013 July 09
    View PubMed
  353. Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol. 2013 Aug; 88(8):690-3. Epub 2013 Jun 20.
    View PubMed
  354. Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia. 2013 Aug; 27 (8):1617-20 Epub 2013 Apr 05
    View PubMed
  355. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35. Epub 2013 May 23.
    View PubMed
  356. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54 (8):1713-8 Epub 2012 Dec 31
    View PubMed
  357. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul; 27: (7)1504-10.
    View PubMed
  358. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6; 121(23):4778-81. Epub 2013 Apr 16.
    View PubMed
  359. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013 Jun; 88(6):507-16.
    View PubMed
  360. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma. 2013 Jun; 54(6):1151-8. Epub 2012 Dec 10.
    View PubMed
  361. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2013 Jun; 54 (6):1263-7 Epub 2012 Nov 19
    View PubMed
  362. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun; 27 (6):1322-7 Epub 2013 Mar 05
    View PubMed
  363. Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 2013 Jun; 88 (6):534-5 Epub 2013 May 13
    View PubMed
  364. Al-Kali A, Quintas-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. Epub 2013 Mar 20.
    View PubMed
  365. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013 Apr; 88(4):312-6. Epub 2013 Feb 28.
    View PubMed
  366. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28; 121(13):2393-401. Epub 2013 Jan 16.
    View PubMed
  367. Singal AK, Kamath PS, Tefferi A. Mesenteric venous thrombosis. Mayo Clin Proc. 2013 Mar; 88 (3):285-94 Epub 2013 Feb 27
    View PubMed
  368. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013 Mar; 88 (3):201-6 Epub 2013 Jan 18
    View PubMed
  369. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013 Feb; 88(2):141-50.
    View PubMed
  370. Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res. 2012 Dec; 36(12):1481-9. Epub 2012 Aug 21.
    View PubMed
  371. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20; 30 (33):4098-103 Epub 2012 Oct 15
    View PubMed
  372. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012 Nov 15; 120 (20):4168-71 Epub 2012 Sept 11
    View PubMed
  373. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, Tefferi A. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012 Nov; 87 (11):1003-5 Epub 2012 Sept 11
    View PubMed
  374. Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1053-64. Epub 2012 Aug 21.
    View PubMed
  375. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, Demory JL, Rumi E, Guglielmelli P, Roncoroni E, Tefferi A, Pereira A. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012 Aug 20; 30(24):2981-7. Epub 2012 Jul 23.
    View PubMed
  376. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Mullauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012 Aug 9; 120(6):1197-201. Epub 2012 Jun 26.
    View PubMed
  377. Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012 Jul 19; 120(3):569-71. Epub 2012 Jun 13.
    View PubMed
  378. Bleeker JS, Syed FF, Cooper LT, Weiler CR, Tefferi A, Pardanani A. Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. Am J Hematol. 2012 Jul; 87 (7):703-6 Epub 2012 Feb 24
    View PubMed
  379. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012 Jul; 87(7):669-72. Epub 2012 May 10.
    View PubMed
  380. Hussain FT, Nguyen EP, Raza S, Knudson R, Pardanani A, Hanson CA, Van Dyke, Tefferi A. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Am J Hematol. 2012 Jul; 87(7):684-6. Epub 2012 May 06.
    View PubMed
  381. Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP, Lasho TL, Tefferi A. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012 Jun 14; 119 (24):5674-7 Epub 2012 Apr 26
    View PubMed
  382. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012 Jun; 87 (6):610-9
    View PubMed
  383. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. Epub 2012 Mar 28.
    View PubMed
  384. Sulai NH, Tefferi A. Why does my patient have thrombocytosis? Hematol Oncol Clin North Am. 2012 Apr; 26(2):285-301, viii.
    View PubMed
  385. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012 Apr; 26(4):716-9. Epub 2011 Sep 16.
    View PubMed
  386. Pardanani A, Lasho TL, Finke CM, Rajkumar SV, Singh PP, Ketterling RP, Hanson CA, Katzmann JA, Tefferi A. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012 Apr 1; 30(10):1087-94. Epub 2012 Feb 13.
    View PubMed
  387. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, Tefferi A. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012 Apr; 26 (4):693-9 Epub 2011 Sept 13
    View PubMed
  388. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012 Mar 22; 119 (12):2721-30 Epub 2012 Jan 25
    View PubMed
  389. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Mullauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012 Mar 8; 119(10):2239-41. Epub 2012 Jan 13.
    View PubMed
  390. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012 Mar; 87(3):285-93.
    View PubMed
  391. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol. 2012 Mar; 88(3):237-43. Epub 2011 Nov 17.
    View PubMed
  392. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, McClure RF, Pardanani A. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012 Mar; 26 (3):475-80 Epub 2011 Sept 13
    View PubMed
  393. Vaa BE, Wolanskyj AP, Roeker L, Pardanani A, Lasho TL, Finke CM, Tefferi A. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol. 2012 Feb; 87(2):136-8. Epub 2011 Nov 12.
    View PubMed
  394. Raza S, Viswanatha D, Frederick L, Lasho T, Finke C, Knudson R, Ketterling R, Pardanani A, Tefferi A. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012 Feb; 87(2):204-6. Epub 2011 Nov 4.
    View PubMed
  395. Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Mulligan C, Lee FY, Woolfson A, Lasho TL, Pardanani A, Tefferi A, Lorenzi MV. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb; 26(2):280-8. Epub 2011 Oct 21.
    View PubMed
  396. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119 (2):569-72 Epub 2011 Nov 17
    View PubMed
  397. Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, Gisslinger H, Passamonti F, Tefferi A, Barbui T. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment. Haematologica. 2012; 97(3):475 e5-6.
  398. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012 Jan; 87(1):66-8. Epub 2011 Nov 12.
    View PubMed
  399. Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol. 2012; 87(2):203-4.
    View PubMed
  400. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26):5128-33.
    View PubMed
  401. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012 Jan; 26 (1):101-5 Epub 2011 Oct 28
    View PubMed
  402. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan; 87 (1):25-33
    View PubMed
  403. Pardanani A, Drake MT, Finke C, Lasho TL, Rozell SA, Jimma T, Tefferi A. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Am J Hematol. 2011 Dec; 86(12):1013-6.
    View PubMed
  404. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2011 Dec; 86(12):1017-26.
    View PubMed
  405. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011 Dec; 86 (12):1188-91 Epub 2011 Oct 27
    View PubMed
  406. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011 Dec; 25(12):1834-9. Epub 2011 Jun 21.
    View PubMed
  407. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1; 117 (21):4869-4877 Epub 2011 Apr 08
    View PubMed
  408. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Pardanani A. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood. 2011 Oct 27; 118 (17):4595-8 Epub 2011 Aug 31
    View PubMed
  409. Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D'Agati VD, Nasr SH. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011 Oct; 80(7):753-9. Epub 2011 Jun 8
    View PubMed
  410. Mughal TI, Radich JP, Van Etten RA, Quintas-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep; 86(9):811-9.
    View PubMed
  411. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011 Sep; 25(5):229-37. Epub 2011 Jul 13.
    View PubMed
  412. Tefferi A, Noel P, Hanson CA. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2011 Sep; 13 (5):461-6 Epub 2011 June 30
    View PubMed
  413. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Mullauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011 Aug 10; 29(23):3179-84. Epub 2011 Jul 11.
    View PubMed
  414. Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011 Aug; 86(8):701-2. Epub 2011 Jun 14.
    View PubMed
  415. Thoennissen NH, Lasho T, Thoennissen GB, Ogawa S, Tefferi A, Koeffler HP. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol. 2011 Aug; 86(8):703-5. Epub 2011 Jun 14.
    View PubMed
  416. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14; 118(2):401-8. Epub 2011 May 02.
    View PubMed
  417. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A, Pardanani A, Lin FT, Li J, Sha B, Benveniste EN. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood. 2011 Jul 7; 118(1):156-66. Epub 2011 Apr 28.
    View PubMed
  418. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011 Jul; 86 (7):610-1 Epub 2011 May 31
    View PubMed
  419. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011 Jun 2; 117(22):5857-9. Epub 2011 Apr 13.
    View PubMed
  420. Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, Pardanani A, Tefferi A. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011 May 26; 117 (21):5612-5 Epub 2011 Mar 30
    View PubMed
  421. Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol. 2011 May; 86 (5):393-8
    View PubMed
  422. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011 Apr 1; 29 (10):1356-63 Epub 2011 Feb 07
    View PubMed
  423. Khezri F, Gibson LE, Tefferi A. Xanthoma disseminatum: effective therapy with 2-chlorodeoxyadenosine in a case series. Arch Dermatol. 2011 Apr; 147 (4):459-64 Epub 2010 Dec 20
    View PubMed
  424. Raza S, TaherNazerHussain F, Patnaik M, Knudson R, Van Dyke, Tefferi A. Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Am J Hematol. 2011 Apr; 86(4):353-6.
    View PubMed
  425. Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011 Apr; 86: (4)343-5.
    View PubMed
  426. Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma. 2011 Apr; 52 (4):560-6 Epub 2011 Feb 21
    View PubMed
  427. Tefferi A. How I treat myelofibrosis. Blood. 2011 Mar 31; 117 (13):3494-504 Epub 2011 Jan 03
    View PubMed
  428. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 1; 29 (7):789-96 Epub 2011 Jan 10
    View PubMed
  429. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011 Mar; 18 (2):105-10
    View PubMed
  430. Tefferi A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011 Mar; 86(3):292-301.
    View PubMed
  431. Tefferi A. ASH 2010 meeting report-Top 10 clinically-oriented abstracts in myeloproliferative neoplasms. Am J Hematol. 2011 Mar; 86 (3):333-6
    View PubMed
  432. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20; 29(6):761-70. Epub 2011 Jan 04.
    View PubMed
  433. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, Harr MW, Levine RL, Xu H, Tefferi A, Deblasio A, Hatlen M, Menendez S, Nimer SD. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011 Feb 15; 19(2):283-94.
    View PubMed
  434. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011 Feb 10; 29(5):573-82. Epub 2011 Jan 10.
    View PubMed
  435. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb; 25(2):301-4. Epub 2010 Nov 05.
    View PubMed
  436. Pardanani A, Vannucchi AM, Pardanani A, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011 Feb; 25 (2):218-25 Epub 2010 Nov 16
    View PubMed
  437. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2011 Feb; 25(2):266-70. Epub 2010 Nov 12.
    View PubMed
  438. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1; 29 (4):392-7 Epub 2010 Dec 13
    View PubMed
  439. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke, Hanson C, Pardanani A, Tefferi A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011 Jan; 25(1):82-8. Epub 2010 Oct 14.
    View PubMed
  440. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J. 2011; 1:e7. Epub 2011 Mar 04.
    View PubMed
  441. Brugnara C, Tefferi A. The American Journal of Hematology, 2011 and beyond. Am J Hematol. 2011; 86(1):1.
  442. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011 Jan; 86(1):96-8.
    View PubMed
  443. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010 Nov 25; 116 (22):4436-8 Epub 2010 July 22
    View PubMed
  444. Tefferi A. Myelodysplastic syndromes--many new drugs, little therapeutic progress. Mayo Clin Proc. 2010 Nov; 85 (11):1042-5 Epub 2010 Sept 22
    View PubMed
  445. Pardanani A, Lasho T, Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010 Oct; 24 (10):1713-8 Epub 2010 Aug 19
    View PubMed
  446. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010 Oct; 95 (10):1788-91
    View PubMed
  447. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
    View PubMed
  448. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010 Sep; 40(9):828-34. Epub 2010 Jul 01.
    View PubMed
  449. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol. 2010 Sep; 85(3):192-9. Epub 2010 Jun 02.
    View PubMed
  450. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010 Sep; 85 (9):675-86
    View PubMed
  451. Wadleigh M, Tefferi A. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors. Clin Adv Hematol Oncol. 2010 Aug; 8(8):557-63.
    View PubMed
  452. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Jul; 24 (7):1302-9 Epub 2010 May 27
    View PubMed
  453. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010 Jul; 24 (7):1283-9 Epub 2010 May 20
    View PubMed
  454. Lakey MA, Pardanani A, Hoyer JD, Nguyen PL, Lasho TL, Tefferi A, Hanson CA. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol. 2010 Jun; 133(6):942-8.
    View PubMed
  455. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010 Jun; 24 (6):1146-51 Epub 2010 Apr 22
    View PubMed
  456. Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol. 2010 Jun; 84(6):518-24. Epub 2010 Mar 11.
    View PubMed
  457. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010 Jun; 24 (6):1128-38 Epub 2010 Apr 29
    View PubMed
  458. Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010 May; 84(5):371-8. Epub 2010 Jan 05.
    View PubMed
  459. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Muller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010 Apr 8; 115(14):2882-90. Epub 2010 Jan 12.
    View PubMed
  460. Tefferi A. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leuk Lymphoma. 2010 Apr; 51 (4):576-82
    View PubMed
  461. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010 Apr; 85(4):238-42.
    View PubMed
  462. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 Mar 4; 115(9):1703-8. Epub 2009 Dec 14
    View PubMed
  463. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol. 2010 Mar; 17(2):125-32.
    View PubMed
  464. Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol. 2010 Mar; 85(3):160-3.
    View PubMed
  465. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol. 2010 Mar; 84(3):191-200. Epub 2009 Nov 30.
    View PubMed
  466. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010 Mar; 91(2):174-9. Epub 2010 Feb 27.
    View PubMed
  467. Tefferi A, Pardanani A. Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. Leuk Lymphoma. 2010 Mar; 51 (3):360-2
    View PubMed
  468. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010 Feb; 85 (2):158-64 Epub 2010 Jan 06
    View PubMed
  469. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010 Feb 1; 84(2):105-8. Epub 2009 Nov 06.
    View PubMed
  470. Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol. 2010 Feb; 85(2):93-4.
    View PubMed
  471. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010 Jan 21; 115 (3):496-9 Epub 2009 Nov 09
    View PubMed
  472. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010 Jan; 24(1):105-9. Epub 2009 Oct 22.
    View PubMed
  473. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010 Jan; 85(1):14-7.
    View PubMed
  474. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010 Jan; 24(1):110-4. Epub 2009 Oct 22.
    View PubMed
  475. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009 Dec 15; 115(24):5740-5.
    View PubMed
  476. Esfandyari T, Tefferi A, Szmidt A, Alain T, Zwolak P, Lasho T, Lee PW, Farassati F. Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. Mol Oncol. 2009 Dec; 3(5-6):464-8. Epub 2009 Jul 28.
    View PubMed
  477. Vaidya R, Siragusa S, Huang J, Schwager SM, Hanson CA, Hussein K, Pardanani A, Tefferi A. Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc. 2009 Dec; 84 (12):1114-9
    View PubMed
  478. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec; 84 (12):790-4
    View PubMed
  479. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009 Nov 5; 361 (19):1872-85
    View PubMed
  480. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6 (11):627-37 Epub 2009 Oct 06
    View PubMed
  481. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009 Oct 29; 114 (18):3769-72 Epub 2009 Aug 27
    View PubMed
  482. Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. Am J Hematol. 2009 Oct; 84 (10):629-30
    View PubMed
  483. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27 (27):4563-9 Epub 2009 Aug 03
    View PubMed
  484. Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep; 14(3):471-9.
    View PubMed
  485. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009 Sep 1; 115 (17):3842-7
    View PubMed
  486. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33 (9):1199-203 Epub 2009 Feb 27
    View PubMed
  487. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009 Aug; 23: (8)1441-5.
    View PubMed
  488. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51. Epub 2009 Apr 8
    View PubMed
  489. Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009 Jul; 83(1):17-21. Epub 2009 Feb 19.
    View PubMed
  490. Patnaik MM, Tefferi A. Molecular diagnosis of myeloproliferative neoplasms. Expert Rev Mol Diagn. 2009 Jul; 9(5):481-92.
    View PubMed
  491. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009 Jun 4; 113 (23):5727-36 Epub 2009 Apr 10
    View PubMed
  492. Fink SR, Belongie KJ, Paternoster SF, Smoley SA, Pardanani AD, Tefferi A, Van Dyke DL, Ketterling RP. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res. 2009 Jun; 33 (6):843-6 Epub 2008 Dec 31
    View PubMed
  493. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol. 2009 Jun; 85(6):957-65. Epub 2009 Mar 17.
    View PubMed
  494. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009 May; 82(5):329-38. Epub 2009 Jan 9
    View PubMed
  495. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009 May; 82 (5):350-3 Epub 2009 Jan 06
    View PubMed
  496. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009 May; 23(5):834-44. Epub 2009 Mar 19.
    View PubMed
  497. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009 May-Jun; 59(3):171-91. Epub 2009 Apr 15.
    View PubMed
  498. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84 (5):265-7
    View PubMed
  499. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23 (5):905-11 Epub 2009 Mar 05
    View PubMed
  500. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 May; 23 (5):900-4 Epub 2009 Mar 05
    View PubMed
  501. Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J, Bale S, Compton J, LeDuc CA, Pardanani A, Thorland EC, Shevchenko Y, Grodman M, Chung WK. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res. 2009 May; 33(5):662-4. Epub 2008 Oct 19.
    View PubMed
  502. Chen D, Hoyer JD, Ketterling RP, Tefferi A, Steensma DP, Holtan SG, Santana-Davila R, Porrata LF, Dewald GW, Hanson CA. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q. Leukemia 2009 Apr; 23 (4):796-800 Epub 2008 Oct 23
    View PubMed
  503. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009 Apr; 82(4):255-9. Epub 2008 Feb 10
    View PubMed
  504. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med. 2009 Feb; 13 (2):215-37 Epub 2008 Oct 23
    View PubMed
  505. Tefferi A, Levine RL, Kantarjian H. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):114-9.
    View PubMed
  506. Tefferi A. Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases. Cancer Treat Res. 2009; 148:157-79.
    View PubMed
  507. Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk Res. 2008 Dec; 32(12):1927-30. Epub 2008 Jun 09.
    View PubMed
  508. Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Hanson CA, Tefferi A. Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. Leuk Res. 2008 Oct; 32(10):1597-600. Epub 2008 Feb 1
    View PubMed
  509. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol. 2008 Sep; 83(9):708-13.
    View PubMed
  510. Malhotra P, Hogan WJ, Litzow MR, Elliott MA, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Tefferi A. Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma. 2008 Sep; 49 (9):1724-30
    View PubMed
  511. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol. 2008 Aug; 83 (8):611-3
    View PubMed
  512. Gangat N, Tefferi A. Pharmacotherapy of essential thrombocythemia. Expert Opin Pharmacother. 2008 Jul; 9 (10):1679-85
    View PubMed
  513. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008 Jul; 22(7):1299-307. Epub 2008 May 22.
    View PubMed
  514. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008 Jun 15; 112(12):2726-32.
    View PubMed
  515. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15.
    View PubMed
  516. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol. 2008 Jun; 83(6):451-3.
    View PubMed
  517. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008 Jun; 83(6):491-7.
    View PubMed
  518. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008 May; 83(5):363-5.
    View PubMed
  519. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol. 2008 May; 80(5):386-90. Epub 2008 Jan 23.
    View PubMed
  520. Hussein K, Ketterling RP, Hulshizer RL, Kuffel DG, Wiktor AE, Hanson CA, Tefferi A, Van Dyke DL. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol. 2008 Apr; 80(4):318-21. Epub 2007 Dec 18
    View PubMed
  521. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008 Apr; 22 (4):756-61 Epub 2008 Jan 24
    View PubMed
  522. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008 Apr; 83(4):457-9.
    View PubMed
  523. Werning G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr; 13(4):311-20.
  524. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr; 13(4):321-30.
    View PubMed
  525. Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leuk Res. 2008 Mar; 32(3):407-11. Epub 2007 Aug 20.
    View PubMed
  526. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008 Mar; 49 (3):388-97
    View PubMed
  527. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008 Mar 1; 111 (5):2785-9 Epub 2007 Nov 15
    View PubMed
  528. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY, Ketterling RP, Tefferi A. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2008 Mar; 80(3):197-200. Epub 2007 Dec 07.
    View PubMed
  529. Knoll B, Rea DJ, Szoztek J, Nagorney DS, Tefferi A, Mesa RA. Extramedullary hematopoiesis. Am J Hematol. 2008 Feb; 83 (2):171
    View PubMed
  530. Pardanani A, Tefferi A. Primary eosinophilic disorders: a concise review. Curr Hematol Malig Rep. 2008 Jan; 3 (1):37-43
    View PubMed
  531. Lim KH, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol. 2008; 119(4):194-8. Epub 2008 Jun 20.
    View PubMed
  532. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008 Jan; 22(1):3-13. Epub 2007 Sep 20.
    View PubMed
  533. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008 Jan; 22 (1):14-22 Epub 2007 Sept 20
    View PubMed
  534. Tefferi A. Primary myelofibrosis. Cancer Treat Res. 2008; 142:29-49.
    View PubMed
  535. Tefferi A. Mutant molecules of interest in myeloproliferative neoplasms: introduction. Acta Haematol. 2008; 119(4):192-3. Epub 2008 Jun 20.
    View PubMed
  536. Ho CL, Kito H, Squillace DL, Lasho TL, Tefferi A. Clinical correlates of serum pro-major basic protein in a spectrum of eosinophilic disorders and myelofibrosis. Acta Haematol. 2008; 120(3):158-64. Epub 2008 Nov 28.
    View PubMed
  537. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood. 2007 Dec 15; 110 (13):4172-4 Epub 2007 Oct 01
    View PubMed
  538. Steensma DP, Porcher JC, Hanson CA, Lathrop CL, Hoyer JD, Lasho TA, Tefferi A, Higgs DR. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol. 2007 Nov; 139 (3):439-42
    View PubMed
  539. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007 Nov; 31(11):1503-9. Epub 2007 Mar 29.
    View PubMed
  540. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J. 2007 Nov-Dec; 13(6):366-71.
    View PubMed
  541. Landstrom AP, Knudson RA, Dewald GW, Ketterling RP, Tefferi A. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. Leuk Lymphoma. 2007 Nov; 48 (11):2137-40
    View PubMed
  542. Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leuk Res. 2007 Oct; 31 (10):1389-92 Epub 2007 Feb 27
    View PubMed
  543. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007 Sep; 7(9):673-83.
    View PubMed
  544. Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leuk Res. 2007 Sep; 31 (9):1185-9 Epub 2006 Nov 27
    View PubMed
  545. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007 Sep; 21 (9):1960-3 Epub 2007 June 28
    View PubMed
  546. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21.
    View PubMed
  547. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007 Sep; 25(9):2358-62. Epub 2007 May 31.
    View PubMed
  548. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15; 110 (4):1092-7 Epub 2007 May 08
    View PubMed
  549. Patnaik MM, Tefferi A, Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets. 2007 Aug; 7(5):492-503.
    View PubMed
  550. Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007 Aug; 82(8):958-66.
    View PubMed
  551. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug; 21(8):1658-68. Epub 2007 May 31.
    View PubMed
  552. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007 Aug; 138(3):354-8.
    View PubMed
  553. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007 Aug; 21(8):1827-8. Epub 2007 Apr 26.
    View PubMed
  554. Segovis CM, Mueller PS, Rethlefsen ML, LaRusso NF, Litin SC, Tefferi A, Habermann TM. If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center. BMC Med Educ. 2007 Jul 12; 7:22 Epub 2007 July 12
    View PubMed
  555. Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404. Epub 2007 May 10.
    View PubMed
  556. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007 Jul; 82 (7):864-73
    View PubMed
  557. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31 (6):737-40 Epub 2007 Jan 08
    View PubMed
  558. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007 Jun; 33(4):313-20.
    View PubMed
  559. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007 Jun 1; 109(11):2279-84.
    View PubMed
  560. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007 May 15; 109 (10):2083-8
    View PubMed
  561. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007 May; 131(5):784-91.
    View PubMed
  562. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res. 2007 May; 31: (5)691-4.
    View PubMed
  563. Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc. 2007 May; 82 (5):599-604
    View PubMed
  564. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007 Mar 1; 6 (5):550-66 Epub 2007 Mar 24
    View PubMed
  565. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007 Mar; 14(2):115-22.
    View PubMed
  566. Jensen AW, Tefferi A, Arndt CA. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. J Pediatr Hematol Oncol. 2007 Mar; 29(3):156-9.
    View PubMed
  567. Hogan WJ, Litzow MR, Tefferi A. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep. 2007 Feb; 2 (1):34-42
    View PubMed
  568. Tefferi A. The recent advances in classic BCR-ABL-negative myeloproliferative disorders. Clin Adv Hematol Oncol. 2007 Feb; 5(2):113-5.
    View PubMed
  569. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, Tefferi A. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007 Feb; 21 (2):270-6 Epub 2006 Dec 14
    View PubMed
  570. Arora B, Tefferi A. Advances in molecular diagnostics of myeloproliferative disorders. Expert Opinion on Medical Diagnostics. 2007; 1(1):65-80.
  571. Tefferi A, O'Brien S. Chronic lymphocytic leukemia in 2007: Prognostic factors and therapeutic approaches. Community Oncol. 2007; 4(12 SUPPL. 5):11-6.
  572. Tefferi A. The granulocyte connection in MPD-associated thrombosis. Blood. 2007; 109(6):2270-1.
  573. Silver RT, Bennett JM, Goldman JM, Spivak JL, Tefferi A. The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes. Leuk Res. 2007 Jan; 31(1):11-7.
    View PubMed
  574. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 1; 109(1):315-22.
    View PubMed
  575. Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park). 2007 Jan; 21 (1):43-54; discussion 57-8, 62
    View PubMed
  576. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 1; 109 (1):68-76
    View PubMed
  577. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica. 2006 Dec; 91(12 Suppl):ECR57.
    View PubMed
  578. Tefferi A. Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests. Semin Cardiothorac Vasc Anesth. 2006 Dec; 10(4):282-90.
    View PubMed
  579. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006 Dec; 135(5):683-7.
    View PubMed
  580. Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec; 30(12):1499-505. Epub 2006 May 08.
    View PubMed
  581. Verstovsek S, Quintas-Cardama A, Kantarjian H, Tefferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006 Dec; 15(12):1555-63.
    View PubMed
  582. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108 (10):3472-6 Epub 2006 July 25
    View PubMed
  583. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res. 2006 Nov; 30(11):1457-60. Epub 2006 Mar 23.
    View PubMed
  584. Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov; 30(11):1365-70. Epub 2006 Jun 23.
    View PubMed
  585. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006 Oct; 20 (10):1800-8 Epub 2006 July 27
    View PubMed
  586. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol. 2006 Oct; 77(4):327-33. Epub 2006 Jul 19.
    View PubMed
  587. Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma. 2006 Oct; 47 (10):2055-61
    View PubMed
  588. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 1; 108 (5):1497-503 Epub 2006 May 04
    View PubMed
  589. Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus RD, Vukov A, Li CY, Menke DM, Geyer SM, Alberts SR, North Central Cancer Treatment Group. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer. 2006 Aug 15; 107(4):767-72.
    View PubMed
  590. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108 (4):1158-64 Epub 2006 Apr 11
    View PubMed
  591. Kamineni P, Baptiste A, Hassan M, Dawkins FW, Zaidi S, Tefferi A, Lindsey M, Taddesse-Heath L. Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C. J Natl Med Assoc. 2006 Aug; 98(8):1356-60.
    View PubMed
  592. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006 Aug; 30: (8)965-70.
    View PubMed
  593. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006 Jul 15; 107(2):361-70.
    View PubMed
  594. Tefferi A. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F). Curr Hematol Malig Rep. 2006 Jun; 1 (2):81-6
    View PubMed
  595. Dingli D, Tefferi A. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep. 2006 Jun; 1 (2):69-74
    View PubMed
  596. Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer. 2006 Jun 1; 106(11):2406-11.
    View PubMed
  597. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun; 133 (5):468-92
    View PubMed
  598. Tefferi A, Dingli D, Li CY, Mesa RA. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res. 2006 Jun; 30 (6):677-80 Epub 2005 Nov 08
    View PubMed
  599. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res. 2006 Jun; 30(6):739-44. Epub 2006 Feb 07.
    View PubMed
  600. Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol. 2006 Jun; 133 (6):638-41
    View PubMed
  601. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Litzow MR. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006 Jun; 37(11):1003-8.
    View PubMed
  602. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 2006 Jun; 37(11):1017-22.
    View PubMed
  603. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006 Jun; 20: (6)971-8.
    View PubMed
  604. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer. 2006 May 1; 106(9):1985-9.
    View PubMed
  605. Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer. 2006 Apr 15; 106(8):1739-43.
    View PubMed
  606. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc. 2006 Apr; 81(4):553-63.
    View PubMed
  607. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol. 2006 Mar; 13(2):93-8.
    View PubMed
  608. Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr Opin Hematol. 2006 Mar; 13(2):87-92.
    View PubMed
  609. Landstrom AP, Tefferi A. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma. 2006 Mar; 47 (3):397-402
    View PubMed
  610. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer. 2006 Feb 1; 106(3):623-30.
    View PubMed
  611. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006 Feb; 81 (2):159-66
    View PubMed
  612. Tefferi A. Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clin Proc. 2006 Feb; 81 (2):197-8
    View PubMed
  613. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006 Feb 1; 106 (3):631-5
    View PubMed
  614. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006 Jan; 20(1):29-34.
    View PubMed
  615. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program. 2006; 240-5.
    View PubMed
  616. Tefferi A, Gilliland G. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol. 2006; 19(3):365-85.
    View PubMed
  617. Tefferi A. The diagnosis of polycythemia vera: new tests and old dictums. Best Pract Res Clin Haematol. 2006; 19(3):455-69.
    View PubMed
  618. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol. 2006; 19(3):495-517.
    View PubMed
  619. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlovic S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006; 8 (3):290-8
    View PubMed
  620. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005 Nov 20; 23 (33):8520-30
    View PubMed
  621. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005 Nov; 131 (3):320-8
    View PubMed
  622. Tefferi A, Dingli D, Li CY, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005 Oct 15; 104(8):1656-60.
    View PubMed
  623. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005 Oct; 131 (2):208-13
    View PubMed
  624. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol. 2005 Oct; 42(4):206-20.
    View PubMed
  625. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005 Oct; 131 (2):166-71
    View PubMed
  626. Yoong Y, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Litzow MR, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Tefferi A, Elliott M, Snow DS, Hogan WJ, Markovic SN. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 Sep; 46 (9):1287-94
    View PubMed
  627. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC, Afessa B. Pulmonary complications in adult blood and marrow transplant recipients - Autopsy findings. Chest. 2005 Sep; 128(3):1385-92.
    View PubMed
  628. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005 Sep; 80(9):1220-32.
    View PubMed
  629. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15; 106 (4):1207-9 Epub 2005 Apr 28
    View PubMed
  630. Tefferi A, Rajkumar SV, Adjei AA. Introduction to a cancer symposium for the practitioner. Mayo Clin Proc. 2005 Aug; 80(8):1085-6.
    View PubMed
  631. Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle. 2005 Aug; 4 (8):1053-6 Epub 2005 Aug 26
    View PubMed
  632. Mesa RA, Tefferi A. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):403-13.
    View PubMed
  633. Odenike O, Tefferi A. Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):422-31.
    View PubMed
  634. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia - Evaluation of performance and practical utility. Cancer. 2005 Jul 1; 104(1):213-5.
    View PubMed
  635. Wilson F, Tefferi A. Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review. Leuk Lymphoma. 2005 Jul; 46 (7):1045-50
    View PubMed
  636. Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A. Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol. 2005 Jul; 130(2):229-32.
    View PubMed
  637. Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc. 2005 Jul; 80 (7):923-36
    View PubMed
  638. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005 Jul; 80(7):947-58.
    View PubMed
  639. Kumagai T, Tefferi A, Jones L, Koeffler HP. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res. 2005 May; 29(5):511-5.
    View PubMed
  640. Dingli D, Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma. 2005 May; 46 (5):641-50
    View PubMed
  641. Jones LC, Tefferi A, Vuong PT, Desmond JC, Hofmann WK, Koeffler HP. Detection of aberrant gene expression in CD34(+) hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells. 2005 May; 23(5):631-7.
    View PubMed
  642. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska L, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Gilliland DG, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
    View PubMed
  643. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005 Mar; 80(3):390-402.
    View PubMed
  644. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005 Feb; 19(2):313-7.
    View PubMed
  645. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005 Feb; 128(3):275-90.
    View PubMed
  646. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005 Feb 1; 105 (3):973-7 Epub 2004 Sept 23
    View PubMed
  647. Nowakowski GS, Morice WG, Phyliky RL, Li CY, Tefferi A. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. Br J Haematol. 2005 Feb; 128: (4)490-2.
    View PubMed
  648. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case. Leuk Res. 2005 Feb; 29(2):131-4.
    View PubMed
  649. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Feb; 74(2):117-20.
    View PubMed
  650. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ, Ansell SM, Micallef INM, Gastineau DA, Elliott M, Hogan WJ, Hayman SR, Tefferi A, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res. 2005 Feb 1; 11 (3):1210-8
    View PubMed
  651. Yoong Y, VanDeWalker TJ, Carlson RO, Dewald GW, Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol. 2005 Feb; 74(2):124-7.
    View PubMed
  652. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005 Jan; 19: (1)118-25.
    View PubMed
  653. Ho CL, Arora B, Hoyer JD, Wellik LE, Mesa RA, Tefferi A. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):35-9.
    View PubMed
  654. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):47-53.
    View PubMed
  655. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2005 Jan; 128(1):42-8.
    View PubMed
  656. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005; 114: (1)52-60.
    View PubMed
  657. Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005 Jan; 80(1):75-83.
    View PubMed
  658. Tefferi A. The indolent natural history of essential thrombocythemia: a challenge to new drug development. Mayo Clin Proc. 2005 Jan; 80(1):97-8.
    View PubMed
  659. Arora B, Mesa R, Tefferi A. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 2004 Dec; 45 (12):2373-86
    View PubMed
  660. Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica. 2004 Dec; 89 (12):1454-8
    View PubMed
  661. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004 Dec; 34(12):1025-31.
    View PubMed
  662. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004 Nov 15; 104 (10):3038-45 Epub 2004 July 29
    View PubMed
  663. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004 Nov 15; 104 (10):3400-7 Epub 2004 July 27
    View PubMed
  664. Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP. RAR beta 2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene. 2004 Oct 14; 23(47):7846-53.
    View PubMed
  665. Koch CA, Lasho TL, Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. Br J Haematol. 2004 Oct; 127 (1):34-9
    View PubMed
  666. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004 Oct 1; 104 (7):1931-9 Epub 2004 May 27
    View PubMed
  667. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104 (6):1881-7 Epub 2004 Mar 25
    View PubMed
  668. Greipp PT, Dewald GW, Tefferi A. Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genet Cytogenet. 2004 Sep; 153(2):170-2.
    View PubMed
  669. Elliott MA, Tefferi A. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Curr Hematol Rep. 2004 Sep; 3(5):344-51.
    View PubMed
  670. Dingli D, Tefferi A. Anagrelide: an update on its mechanisms of action and therapeutic potential. Expert Rev Anticancer Ther. 2004 Aug; 4: (4)533-41.
    View PubMed
  671. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004 Aug; 28 (8):777-83
    View PubMed
  672. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg. 2004 Aug; 240 (2):286-92
    View PubMed
  673. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004 Aug; 45 (8):1545-9
    View PubMed
  674. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004 Jul; 43 (7):540-7
    View PubMed
  675. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004 Jul; 79 (7):883-9
    View PubMed
  676. Tefferi A, Elliott MA. Schistocytes on the peripheral blood smear. Mayo Clin Proc. 2004 Jun; 79 (6):809
    View PubMed
  677. Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol. 2004 Jun; 79 (5):441-7
    View PubMed
  678. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103 (10):3960-3 Epub 2004 Jan 22
    View PubMed
  679. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res. 2004 May; 28 Suppl 1:S47-52.
    View PubMed
  680. Tefferi A, Spelsberg TC. Primer on medical genomics. The end of the beginning. Mayo Clin Proc. 2004 May; 79 (5):659-60
    View PubMed
  681. Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Current Hematology Reports. 2004 May; 3(3):197-202.
    View PubMed
  682. Hook CC, DiMagno EP, Tefferi A. Primer on medical genomics. Part XIII: Ethical and regulatory issues. Mayo Clin Proc. 2004 May; 79 (5):645-50
    View PubMed
  683. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood. 2004 May 1; 103 (9):3547-8 Epub 2003 Dec 30
    View PubMed
  684. Nadrous HF, Krowka MJ, McClure RF, Tefferi A, Lim KG. Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformation. Leuk Lymphoma. 2004 Apr; 45 (4):815-8
    View PubMed
  685. Tefferi A, Nagorney DM. The spleen in myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004 Apr; 79(4):503.
    View PubMed
  686. Tefferi A, Colgan JP. Breast peau d'orange from large cell lymphoma. Mayo Clin Proc. 2004 Feb; 79(2):187.
    View PubMed
  687. Pardanani A, Hoffbrand AV, Pardanani A, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004 Feb; 28 (2):127-31
    View PubMed
  688. Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagulation & Fibrinolysis. 2004 Jan; 15(1):21-4.
    View PubMed
  689. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004; 89(7):871-3.
    View PubMed
  690. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004 Jan; 11 (1):58-64
    View PubMed
  691. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 2003 Dec 15; 102 (13):4512-9 Epub 2003 Aug 14
    View PubMed
  692. Huber MR, Kumar S, Tefferi A. Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol. 2003 Dec; 82(12):723-37.
    View PubMed
  693. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003 Nov 1; 102 (9):3093-6 Epub 2003 July 03
    View PubMed
  694. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003 Nov; 78(11):1340-6.
    View PubMed
  695. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003 Oct; 27 (10):883-5
    View PubMed
  696. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003 Oct; 78 (10):1223-33
    View PubMed
  697. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003 Oct; 78 (10):1274-80
    View PubMed
  698. Neben MA, Morice WG, Tefferi A. Clinical features in T-cell vs. natural killer-cell variants of large granular lymphocyte leukemia. Eur J Haematol. 2003 Oct; 71 (4):263-5
    View PubMed
  699. Steensma DP, Tefferi A, Li CY. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res. 2003 Sep; 27 (9):775-82
    View PubMed
  700. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia. 2003 Sep; 17(9):1865-70.
    View PubMed
  701. Pardanani A, Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet. 2003 Aug 16; 362 (9383):535-6
    View PubMed
  702. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003 Aug; 27 (8):739-42
    View PubMed
  703. Howe R, Micallef INM, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A, Gastineau DA, Gertz MA, Geyer SM, Hanson CA, Lacy MQ, Tefferi A, Litzow MR. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant. 2003 Aug; 32(3):317-24.
    View PubMed
  704. Ensenauer RE, Reinke SS, Ackerman MJ, Tester DJ, Whiteman DA, Tefferi A. Primer on medical genomics. Part VIII: Essentials of medical genetics for the practicing physician. Mayo Clin Proc. 2003 Jul; 78(7):846-57.
    View PubMed
  705. Pardanani AD, Morice WG, Hoyer JD, Tefferi A. Chronic basophilic leukemia: a distinct clinico-pathologic entity? Eur J Haematol. 2003 Jul; 71 (1):18-22
    View PubMed
  706. Afessa B, Tefferi A, Dunn WF, Litzow MR, Peters SG. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit Care Med. 2003 Jun; 31(6):1715-21.
    View PubMed
  707. Chou JM, Li CY, Tefferi A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res. 2003 Jun; 27(6):499-504.
    View PubMed
  708. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol. 2003 Jun; 16 (2):227-42
    View PubMed
  709. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003 May; 78(5):589-98.
    View PubMed
  710. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1; 101 (9):3391-7 Epub 2002 Dec 27
    View PubMed
  711. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia. 2003 May; 17 (5):849-55
    View PubMed
  712. Tefferi A. A contemporary approach to the diagnosis and management of polycythemia vera. Current Hematology Reports. 2003 May; 2(3):237-41.
    View PubMed
  713. Elliott MA, Nichols WL Jr, Plumhoff EA, Ansell SM, Dispenzieri A, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Tefferi A, Litzow M. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc. 2003 Apr; 78 (4):421-30
    View PubMed
  714. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1; 101 (7):2534-41 Epub 2002 Nov 27
    View PubMed
  715. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
    View PubMed
  716. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003 Mar 15; 101 (6):2156-8 Epub 2002 Oct 31
    View PubMed
  717. Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res. 2003 Mar; 27 (3):235-42
    View PubMed
  718. Jimenez TM, Patel SB, Pineda AA, Tefferi A, Owen WG. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion. 2003 Mar; 43(3):328-34.
    View PubMed
  719. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003 Mar 1; 101 (5):1981-3 Epub 2002 Oct 24
    View PubMed
  720. Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc. 2003 Mar; 78(3):301-6.
    View PubMed
  721. Ansell SM, Ackerman MJ, Black JL, Roberts LR, Tefferi A. Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. Mayo Clin Proc. 2003 Mar; 78(3):307-17.
    View PubMed
  722. Morice WG, Kurtin PJ, Leibson PJ, Tefferi A, Hanson CA. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol. 2003 Mar; 120 (6):1026-36
    View PubMed
  723. Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol. 2003 Feb; 120 (4):691-4
    View PubMed
  724. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003 Feb; 27 (2):95-120
    View PubMed
  725. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003 Feb; 78(2):174-94.
    View PubMed
  726. Tefferi A. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. Semin Hematol. 2003 Jan; 40(1 Suppl 1):18-21.
    View PubMed
  727. Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist. 2003; 8 (3):225-31
    View PubMed
  728. Tefferi A. The treatment of myelofibrosis with myeloid metaplasia. Modern Aspects of Immunobiology. 2003; 3(1):22.
  729. Vanness ER, Davis MD, Davis MDP, Tefferi A. Cutaneous findings associated with chronic natural killer cell lymphocytosis. Int J Dermatol. 2002 Dec; 41 (12):852-7
    View PubMed
  730. Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. American Journal of Respiratory & Critical Care Medicine. 2002 Nov 15; 166(10):1364-8.
    View PubMed
  731. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc. 2002 Nov; 77(11):1169-75.
    View PubMed
  732. Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Primer on medical genomics. Part IV: Expression proteomics. Mayo Clin Proc. 2002 Nov; 77(11):1185-96.
    View PubMed
  733. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Litzow MR. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002 Nov; 113 (7):549-55
    View PubMed
  734. Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA Jr, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002 Nov; 43 (11):2099-107
    View PubMed
  735. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 Sep; 118 (3):813-6
    View PubMed
  736. Tefferi A, Bolander ME, Ansell SM, Wieben ED, Spelsberg TC. Primer on medical genomics. Part III: Microarray experiments and data analysis. Mayo Clin Proc. 2002 Sep; 77(9):927-40.
    View PubMed
  737. Gumina RJ, Foley DA, Tefferi A, Rooke TW, Shields RC. Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis. Angiology. 2002 Sep-Oct; 53: (5)587-91.
    View PubMed
  738. Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002 Sep 1; 166 (5):641-5
    View PubMed
  739. Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc. 2002 Aug; 77(8):760-2.
    View PubMed
  740. Lorentz CP, Wieben ED, Tefferi A, Whiteman DA, Dewald GW. Primer on medical genomics part I: History of genetics and sequencing of the human genome. Mayo Clin Proc. 2002 Aug; 77(8):773-82.
    View PubMed
  741. Tefferi A, Wieben ED, Dewald GW, Whiteman DA, Bernard ME, Spelsberg TC. Primer on medical genomics part II: Background principles and methods in molecular genetics. Mayo Clin Proc. 2002 Aug; 77(8):785-808.
    View PubMed
  742. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant. 2002 Aug; 30(3):161-5.
    View PubMed
  743. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul; 16 (7):1311-8
    View PubMed
  744. Melton III LJ, Marquez MA, Achenbach SJ, Tefferi A, O'Connor MK, O'Fallon WM, Riggs BL. Variations in bone density among persons of African heritage. Osteoporos Int. 2002 Jul; 13 (7):551-9
    View PubMed
  745. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002 Jun; 81(6):312-9.
    View PubMed
  746. Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G, Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002 Jun 1; 99 (11):4131-7
    View PubMed
  747. Rao RD, Swanson JW, Dejesus RS, Hunt CH, Tefferi A. Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2002 Jun; 43(6):1333-6.
    View PubMed
  748. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99 (10):3854-6
    View PubMed
  749. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4; 359(9317):1577-8.
    View PubMed
  750. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 May; 117 (2):288-96
    View PubMed
  751. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002 Mar 15; 99 (6):2252-4
    View PubMed
  752. Elliot MA, Yoon SY, Kao P, Li CY, Tefferi A. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2002 Mar; 68 (3):175-9
    View PubMed
  753. Elliott MA, Letendre L, Hanson CA, Tefferi A, Dewald GW. The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. Leuk Lymphoma. 2002 Mar; 43 (3):583-6
    View PubMed
  754. Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res. 2002 Feb; 11 (1):33-47
    View PubMed
  755. Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Bone marrow angiogenesis in systemic mast cell disease. J Hematother Stem Cell Res. 2002 Feb; 11(1):139-46.
    View PubMed
  756. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15; 99 (2):664-71
    View PubMed
  757. Baek JY, Tefferi A, Pardanani A, Li CY. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res. 2002 Jan; 26 (1):83-90
    View PubMed
  758. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002 Jan 1; 99 (1):268-74
    View PubMed
  759. Tefferi A. Current management of polycythemia vera. Leuk Lymphoma. 2002 Jan; 43 (1):1-7
    View PubMed
  760. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002; 108 (2):55-65
    View PubMed
  761. Diehn F, Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol. 2001 Dec; 115 (3):619-21
    View PubMed
  762. Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001 Dec; 115 (4):854-61
    View PubMed
  763. Steensma DP, Tefferi A. Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. Leuk Lymphoma. 2001 Nov-Dec; 42 (6):1229-34
    View PubMed
  764. Steensma DP, Harrison CN, Tefferi A. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Leuk Lymphoma. 2001 Nov-Dec; 42 (6):1243-53
    View PubMed
  765. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001 Nov; 28 (9):895-7
    View PubMed
  766. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 2001 Nov; 28 (10):951-6
    View PubMed
  767. Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Nov; 28(10):997-9.
    View PubMed
  768. Tefferi A, Meyer RG, Wyatt WA, Dewald GW. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Nov; 115 (2):316-9
    View PubMed
  769. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001 Oct; 25 (10):829-38
    View PubMed
  770. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Sep; 28(5):425-34.
    View PubMed
  771. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001 Sep; 120 (3):801-8
    View PubMed
  772. Mesa RA, Tefferi A. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma. 2001 Sep-Oct; 42 (5):901-11
    View PubMed
  773. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001 Sep; 15(3):121-31.
    View PubMed
  774. Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia. 2001 Aug; 15 (8):1171-5
    View PubMed
  775. Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncey T, Appelbaum FR, Guardiola P, Callander N, Freytes C, Gazitt Y, Razvillas B, Deeg HJ. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001 Aug 01; 98: (3)586-93.
    View PubMed
  776. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001 Aug 1; 98 (3):579-85
    View PubMed
  777. Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15; 98 (2):483-5
    View PubMed
  778. Kumar S, Kumar S, Tefferi A. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. Ann Hematol. 2001 Jul; 80 (7):430-5
    View PubMed
  779. Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jul; 114 (1):111-3
    View PubMed
  780. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001 Jun 1; 97 (11):3665-7
    View PubMed
  781. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jun; 113 (3):763-71
    View PubMed
  782. Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Jun; 27 (12):1299-303
    View PubMed
  783. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. Bone Marrow Transplant. 2001 Jun; 27(11):1133-40.
    View PubMed
  784. Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk Res. 2001 May; 25 (5):369-77
    View PubMed
  785. Greenlund LJ, Letendre L, Tefferi A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma. 2001 May; 41 (5-6):571-7
    View PubMed
  786. Schanbacher CF, Vanness ER, Daoud MS, Tefferi A, Su WP. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc. 2001 May; 76 (5):488-92
    View PubMed
  787. Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2001 Apr; 41 (3-4):277-84
    View PubMed
  788. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001 Mar; 66 (3):152-9
    View PubMed
  789. Barron BA, Hoyer JD, Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol. 2001 Mar; 80 (3):166-9
    View PubMed
  790. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001 Feb 15; 97 (4):863-6
    View PubMed
  791. Tefferi A. The pathogenesis of chronic myeloproliferative diseases. Int J Hematol. 2001 Feb; 73 (2):170-6
    View PubMed
  792. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001 Feb; 25 (2):183-5
    View PubMed
  793. Tefferi A. Chronic myeloid disorders: Classification and treatment overview. Semin Hematol. 2001 Jan; 38 (1 Suppl 2):1-4
    View PubMed
  794. Wright CA, Tefferi A. A single institutional experience of 43 pregnancies in essential thrombocythemia. Eu J Haematol. 2001; 65:1-8.
  795. Tefferi A. Leucocytosis and the chronic leukemias. Primary Hematology. 2001; 0: 0.
  796. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001 Jan; 76 (1):22-8
    View PubMed
  797. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2001 Jan; 66 (1):37-42
    View PubMed
  798. Elliott MA, Dewald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001 Jan; 15 (1):35-40
    View PubMed
  799. Yoon SY, Tefferi A, Li CY. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders. Haematologica. 2001 Jan; 86(1):52-7.
    View PubMed
  800. Porrata LF, Litzow MR, Tefferi A, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous hemtopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. J Clin Oncol. 2001; 98: (3)579-85.
  801. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000 Nov 15; 96 (10):3374-80
    View PubMed
  802. Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000 Nov 15; 96 (10):3644-6
    View PubMed
  803. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA, Litzow MR. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000 Nov; 26(9):963-9.
    View PubMed
  804. Yoon SY, Li CY, Lloyd RV, Tefferi A. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. Int J Hematol. 2000 Oct; 72(3):337-42.
    View PubMed
  805. Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mp1 expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol. 2000 Sep; 65(3):170-174.
    View PubMed
  806. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev. 2000 Sep; 14(3):121-9.
    View PubMed
  807. Tefferi A, Elliott MA, Kao PC, Yoon S, El-Hemaidi I, Pearson TC. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood. 2000 Aug 15; 96 (4):1582-4
    View PubMed
  808. Shoho AR, Go RS, Tefferi A. 22-year-old woman with severe microcytic anemia. Mayo Clin Proc. 2000 Aug; 75 (8):861-4
    View PubMed
  809. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med. 2000 Aug 1; 109 (2):141-9
    View PubMed
  810. Steensma DP, Tefferi A, Weiler CR. Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis. Mayo Clin Proc. 2000 Aug; 75(8):853-5.
    View PubMed
  811. Tefferi A, Yoon SY, Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood. 2000 Jul 15; 96 (2):771-2
    View PubMed
  812. Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000 Jul; 26(1):45-50.
    View PubMed
  813. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000 Apr 27; 342 (17):1255-65
    View PubMed
  814. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000 Apr 1; 95 (7):2226-33
    View PubMed
  815. Menke DM, Griesser H, Moder KG, Tefferi A, Luthra HS, Cohen MD, Colon-Otero G, Lloyd RV. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000 Feb; 113(2):212-8.
    View PubMed
  816. Dietz AB, Bulur PA, Erickson MR, Wettstein PJ, Litzow MR, Wyatt WA, Dewald GW, Tefferi A, Pankratz VS, Vuk-Pavlovic S. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematother Stem Cell Res. 2000 Feb; 9 (1):95-101
    View PubMed
  817. Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res. 2000 Jan; 6 (1):237-49
    View PubMed
  818. Tefferi A. Polycythemia Vera: a concise summary of diagnosis, prognosis, and treatment. Cancer Research, Therapy & Control. 2000; 10(4):287-292.
  819. Michiels JJ, Barbui T, Finazzi G, Fruchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A, Thiele J. Diagnosis and treatment of polycytemia vera and possible future study designs of the PVSG. Leukemia Lymphoma. 2000 36; 36:239-53.
    View PubMed
  820. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 2000; 104 (4):151-7
    View PubMed
  821. Mattern SE, Tefferi A. Acute porphyria: the cost of suspicion. Am J Med. 1999 Dec; 107 (6):621-3
    View PubMed
  822. Tefferi A, Levitt R, Li CY, Schroeder G, Tschetter LK, Michalak JC, Krook JE, Witzig TE. Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia. Am J Clin Oncol. 1999 Oct; 22 (5):509-16
    View PubMed
  823. Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev. 1999 Sep; 13(3):163-70.
    View PubMed
  824. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999 Sep; 106 (3):682-8
    View PubMed
  825. Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999 Sep; 106 (4):960-6
    View PubMed
  826. Letendre L, Noel P, Noel P, White WL, Tefferi A, Litzow MR, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res. 1999 Sep; 23 (9):811-5
    View PubMed
  827. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999 May; 61 (1):10-5
    View PubMed
  828. Harewood GC, Loftus EV Jr, Tefferi A, Tremaine WJ, Sandborn WJ. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999 May; 5 (2):98-103
    View PubMed
  829. Hogan WJ, Tefferi A, Borell TJ, Jenkins R, Jenkins R, Li CY, Witzig TE. Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 1999 Apr 15; 110 (2):77-81
    View PubMed
  830. Tefferi A, Inwards DJ, Hoyer JD. Spontaneous remission of anemia associated with a myelodysplastic syndrome with disease evolution into a myeloproliferative state. Acta Haematol. 1999 Mar; 101 (1):50-2
    View PubMed
  831. Tefferi A. Diagnosing polycythemia vera: a paradigm shift. Mayo Clin Proc. 1999 Feb; 74(2):159-62.
    View PubMed
  832. Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999 Feb; 23(3):221-6.
    View PubMed
  833. Tefferi A. Introduction: overview of chronic myeloproliferative disorders. Semin Hematol. 1999 Jan; 36(1 Suppl 2):1-2.
    View PubMed
  834. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Semin Hematol. 1999 Jan; 36(1 Suppl 2):3-8.
    View PubMed
  835. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol. 1999 Jan; 36: (1 Suppl 2)23-5.
    View PubMed
  836. Colon-Otero G, Moreno A, Tefferi A. A critical review of new treatments for the myelodysplastic syndromes. Cancer Research, Therapy & Control. 1999; 9(3-4):281-88.
  837. Schroeder G, Tefferi A, Sargent DJ. Statistical methods frequently used in cancer research. Cancer Research, Therapy & Control. 1999; 9(3-4):333-43.
  838. Tefferi A. Essential Thrombocythemia. Haematology. 1999.
  839. Tefferi A. Essential Thrombocythemia. Education Program and Scientific Supplement of the IX Congress of The International Society of Haematology Asian-Pacific Division. 1999; 89-93.
  840. Tefferi A. Myelofibrosis with Myeloid metaplasia. Education Program and Scientific Supplement of the IX Congress of The International Society of Haematology Asian-Pacific Division. 1999; 0: 97-9.
  841. Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc. 1998 Dec; 73(12):1177-84.
    View PubMed
  842. Tefferi A, Silverstein MN. Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol. 1998 Dec; 11 (4):769-85
    View PubMed
  843. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998 Nov; 103 (2):505-11
    View PubMed
  844. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol. 1998 Nov; 59 (3):230-3
    View PubMed
  845. Fonseca R, Yamakawa M, Nakamura S, van Heerde P, Miettinen M, Shek TW, Myhre Jensen O, Rousselet MC, Tefferi A. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol. 1998 Oct; 59 (2):161-7
    View PubMed
  846. Letendre L, Noel P, Noel P, Litzow MR, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol. 1998 Apr; 21 (2):142-4
    View PubMed
  847. Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Litzow MR. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol. 1998 Mar; 100 (4):680-7
    View PubMed
  848. Tefferi A. Morphology of the blood. Mayo Clin Proc. 1998; 73.
  849. Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997 Dec; 103 (6):536-40
    View PubMed
  850. Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol. 1997 Nov; 99 (2):352-7
    View PubMed
  851. Galanis E, Litzow MR, Tefferi A, Scott JP. Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation. Bone Marrow Transplant. 1997 Oct; 20(8):695-6.
    View PubMed
  852. Solberg LA Jr, Tefferi A, Oles KJ, Tarach JS, Petitt RM, Forstrom LA, Silverstein MN. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol. 1997 Oct; 99 (1):174-80
    View PubMed
  853. Daniell WE, Stockbridge HL, Labbe RF, Woods JS, Anderson KE, Bissel DM, Bloomer JR, Ellefson RD, Moore MR, Pierach CA, Schreiber WE, Tefferi A, Franklin GM. Environmental chemical exposures and disturbances of heme synthesis. Environmental Health Perspectives 5. 1997 10; 105: 37-53.
  854. Gertz MA, Lacy MQ, Inwards DJ, Pineda AA, Chen MG, Gastineau DA, Tefferi A, Kyle RA, Litzow MR. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1997 Sep; 20 (5):375-80
    View PubMed
  855. Elliott MA, Tefferi A, Marshall WF, Lacy MQ. Disseminated nocardiosis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 Sep; 20: (5)425-6.
    View PubMed
  856. Fonseca R, Tefferi A, Strickler JG. Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. Am J Hematol. 1997 Jul; 55 (3):148-55
    View PubMed
  857. Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB, Li CY, Hanson CA, Mesa RA, Phyliky RL. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 1997 Jun; 95 (2):173-7
    View PubMed
  858. Tefferi A, Litzow MR, Noel P, Noel P, Dewald GW. Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. Mayo Clin Proc. 1997 May; 72 (5):445-52
    View PubMed
  859. Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev. 1997 Mar; 11 (1):1-7
    View PubMed
  860. Fonseca R, Tefferi A. Practical aspects in the diagnosis and management of aplastic anemia. Am J Med Sci. 1997 Mar; 313 (3):159-69
    View PubMed
  861. Dewald GW, Juneau AL, Schad CR, Tefferi A. Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia. Cancer Genet Cytogenet. 1997 Mar; 94 (1):59-66
    View PubMed
  862. Tefferi A, Li CY. Bone marrow granulomas associated with chronic natural killer cell lymphocytosis. Am J Hematol. 1997 Mar; 54 (3):258-62
    View PubMed
  863. Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997 Mar; 96 (4):850-3
    View PubMed
  864. Bower JH, Hammack JE, McDonnell SK, Tefferi A. The neurologic complications of B-cell chronic lymphocytic leukemia. Neurology. 1997 Feb; 48 (2):407-12
    View PubMed
  865. Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997; 23 (5):463-72
    View PubMed
  866. Tefferi A, Silverstein MN. Agnogenic myeloid metaplasia. Cancer Invest. 1997; 15 (2):177-9
    View PubMed
  867. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost. 1997; 23: (4)379-83.
    View PubMed
  868. Tefferi A, Bartholmai BJ, Witzig TE, Li CY, Hanson CA, Phyliky RL. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 1996 Oct; 106 (4):457-61
    View PubMed
  869. Tefferi A, Silverstein MN. Current perspective in agnogenic myeloid metaplasia. Leuk Lymphoma. 1996 Sep; 22 Suppl 1:169-71
    View PubMed
  870. Tefferi A, Grendahl DC. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. Am J Hematol. 1996 Jul; 52(3):231-3.
    View PubMed
  871. Okuno SH, Tefferi A, Hanson CA, Katzmann JA, Li CY, Witzig TE. Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Br J Haematol. 1996 Jun; 93(4):810-2.
    View PubMed
  872. Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996 May; 93 (2):406-8
    View PubMed
  873. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996 Apr 1; 87 (7):3000-6
    View PubMed
  874. Rusnak F, Beressi AH, Haddy A, Tefferi A. Calcineurin protein phosphatase activity in peripheral blood lymphocytes. Bone Marrow Transplant. 1996 Mar; 17(3):309-13.
    View PubMed
  875. Tefferi A. Chronic natural killer cell lymphocytosis. Leuk Lymphoma. 1996 Jan; 20 (3-4):245-8
    View PubMed
  876. Fairbanks VF, Klee GG, Wiseman GA, Hoyer JD, Tefferi A, Petitt RM, Silverstein MN. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis. 1996; 22 (2):169-86; discussion 186a-186g
    View PubMed
  877. Okuno SH, Tefferi A, Hanson CA, Katzmann JA, Li CY, Witzig TE. The clinical spectrum of diseases associated with increased proportions of peripheral blood natural killers cells. Brit J Haematol. 1996; 93:810-12.
  878. Bartlett RP, Greipp PR, Tefferi A, Cupps RE, Mullan BP, Trastek VF. Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc. 1995 Dec; 70 (12):1161-4
    View PubMed
  879. Letendre L, Noel P, Noel P, Tefferi A, Solberg LA Jr, Gastineau DA, Hoagland HC. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol. 1995 Oct; 18 (5):382-4
    View PubMed
  880. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med. 1995 Sep; 99 (3):276-81
    View PubMed
  881. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol. 1995 Aug; 22(4):334-40.
    View PubMed
  882. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 1995 Aug; 22(4):327-33.
    View PubMed
  883. Tefferi A, Schad CR, Pruthi RK, Ahmann GJ, Spurbeck JL, Dewald GW. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genet Cytogenet. 1995 Aug; 83 (1):61-4
    View PubMed
  884. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland HC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 1995 Jun 12; 155(11):1217-22.
    View PubMed
  885. Tefferi A. Changing trends in the management of chronic granulocytic leukemia. Int J Oncol. 1995 Jan; 6:163-166.
  886. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994 Oct 15; 84 (8):2721-5
    View PubMed
  887. Ho TC, Tefferi A, Su JQ, Litzow MR, Hoagland HC, Noel P, Noel P. Acute lymphocytic leukemia in adults: a retrospective study and analysis of current management options. Mayo Clin Proc. 1994 Oct; 69 (10):937-48
    View PubMed
  888. Tefferi A, Colgan JP, Solberg LA Jr. Acute porphyrias: diagnosis and management. Mayo Clin Proc. 1994 Oct; 69 (10):991-5
    View PubMed
  889. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994 Oct; 97 (4):374-8
    View PubMed
  890. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994 Sep 1; 84 (5):1620-7
    View PubMed
  891. Witzig TE, Borell TJ, Herath JF, Tefferi A, Li CY, Jenkins RB. Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. Leuk Lymphoma. 1994 Aug; 14 (5-6):447-51
    View PubMed
  892. Tefferi A, Barrett SM, Silverstein MN, Nagorney DM. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol. 1994 Aug; 46 (4):325-8
    View PubMed
  893. Tefferi A, Mathew P, Noel P. The 5q- syndrome: a scientific and clinical update. Leuk Lymphoma. 1994 Aug; 14 (5-6):375-8
    View PubMed
  894. Tefferi A, Hoagland HC. Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc. 1994 Jul; 69 (7):651-5
    View PubMed
  895. Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma. 1994 Jun; 14 (1-2):137-9
    View PubMed
  896. Tefferi A, Solberg LA Jr, Ellefson RD. Porphyrias: clinical evaluation and interpretation of laboratory tests. Mayo Clin Proc. 1994 Mar; 69 (3):289-90
    View PubMed
  897. Witzig TE, Li CY, Tefferi A, Katzmann JA. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 1994 Mar; 101 (3):312-7
    View PubMed
  898. Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol. 1994 Mar; 12 (3):569-74
    View PubMed
  899. Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc. 1994 Feb; 69 (2):144-50
    View PubMed
  900. Dhodapkar M, Goldberg SL, Tefferi A, Gertz MA. Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. Am J Hematol. 1994 Feb; 45 (2):187-8
    View PubMed
  901. Tiede DJ, Tefferi A, Kochhar R, Thompson GB, Hay ID. Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. Cancer. 1994 Feb 1; 73 (3):702-5
    View PubMed
  902. Tefferi A, Pruthi RK. The biochemical basis of cobalamin deficiency. Mayo Clin Proc. 1994 Feb; 69 (2):181-6
    View PubMed
  903. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst. 1993 Sep 15; 85 (18):1520-2
    View PubMed
  904. Dhodapkar M, Tefferi A, Su J, Phyliky RL. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia. 1993 Aug; 7(8):1232-5.
    View PubMed
  905. Noel P, Noel P, Tefferi A, Pierre RV, Jenkins RB, Dewald GW. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 1993 Mar; 7 (1):10-8
    View PubMed
  906. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, Noel P. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood. 1993 Feb 15; 81 (4):1040-5
    View PubMed
  907. Kyle RA, Tefferi A. Multiple myeloma, chronic lymphocytic leukemia, and hairy cell leukemia. Curr Opin Hematol. 1993; 195-200.
  908. Helm KF, Peters MS, Tefferi A, Leiferman KM. Pyoderma gangrenosum-like ulcer in a patient with large granular lymphocytic leukemia. J Am Acad Dermatol. 1992 Nov; 27 (5 Pt 2):868-71
    View PubMed
  909. Neal TF Jr, Tefferi A, Witzig TE, Su J, Phyliky RL, Nagorney DM. Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. Am J Med. 1992 Oct; 93 (4):435-40
    View PubMed
  910. Tefferi A, Wiltsie JC, Kurtin PJ. Secondary T-cell lymphoma in the setting of nodular lymphocyte predominance Hodgkin's disease. Am J Hematol. 1992 Jul; 40 (3):232-3
    View PubMed
  911. Goldberg SL, Tefferi A, Rummans TA, Chen MG, Solberg LA, Noel P. Post-irradiation somnolence syndrome in an adult patient following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 Jun; 9(6):499-501.
    View PubMed
  912. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities. Mayo Clin Proc. 1992 May; 67 (5):457-61
    View PubMed
  913. Tefferi A, Greipp PR, Leibson PJ, Thibodeau SN. Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. Leukemia. 1992 May; 6(5):477-80.
    View PubMed
  914. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis. Mayo Clin Proc. 1992 Apr; 67 (4):349-53
    View PubMed
  915. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG. Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc. 1992 Feb; 67 (2):117-22
    View PubMed
  916. Graham DL, Tefferi A, Letendre L, Gastineau DA, Hoagland HC, Noel P, Noel P. Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc. 1992 Feb; 67 (2):123-7
    View PubMed
  917. Scott FM, Tefferi A. GM-CSF for the treatment of neutropenia associated with large granular lymphocytic leukemia. Am J Hematol. 1992; 39:316.
    View PubMed
  918. Tefferi A, Bren GD, Wagner KV, Schaid DJ, Ash RC, Thibodeau SN. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia. 1990 Dec; 4(12):839-42.
    View PubMed
  919. Tefferi A, Zellers RA, Banks PM, Therneau TM, Colgan JP. Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. J Clin Oncol. 1990 Dec; 8: (12)1959-65.
    View PubMed
  920. Tefferi A, Thibodeau SN, Solberg LA Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood. 1990 May 1; 75 (9):1770-3
    View PubMed
  921. Kipps TJ, Robbins BA, Tefferi A, Meisenholder G, Banks PM, Carson DA. CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies. Am J Pathol. 1990 Apr; 136(4):809-16.
    View PubMed
  922. Solberg LA Jr, Oles KJ, Kimlinger TK, Tefferi A, Katzmann JA, Li CY. A new murine monoclonal antibody for the diagnosis of erythroleukemia. Am J Clin Pathol. 1990 Mar; 93 (3):387-90
    View PubMed
  923. Tefferi A, Nichols WL, Bowie EJ. Circulating heparin-like anticoagulants: report of five consecutive cases and a review. Am J Med. 1990 Feb; 88 (2):184-8
    View PubMed
  924. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990 Feb 1; 171(2):559-64.
    View PubMed
  925. Windebank KP, Tefferi A, Smithson WA, Li CY, Solberg LA Jr, Priest JR, Elliott SC, de Alarcon PA, Weinblatt ME, Burgert EOJ. Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc. 1989 Nov; 64(11):1339-51.
    View PubMed
  926. Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989 Oct; 64 (10):1246-54
    View PubMed
  927. Tefferi A, Li CY, Phyliky RL. Correlation of clinical outcome with the degree of surface immunoglobulin (sIg) expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 1989 Jul; 92 (1):82-5
    View PubMed
  928. Tefferi A, Owen BA, Nichols WL, Witzig TE, Owen WG. Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma. Blood. 1989 Jul; 74 (1):252-4
    View PubMed
  929. Tefferi A, Windebank KP, Veeder MH, Kiely JM. Steroid-responsive pure red cell aplasia associated with natural killer cell lymphocytosis. Am J Hematol. 1989 Jul; 31 (3):211-2
    View PubMed
  930. Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet. 1989 Jun; 39 (2):167-79
    View PubMed
  931. Tefferi A, Solberg LA Jr, Petitt RM, Willis LG. Adult-onset cyclic bicytopenia: a case report and review of treatment of cyclic hematopoiesis. Am J Hematol. 1989 Mar; 30 (3):181-5
    View PubMed
  932. Zelickson BD, Tefferi A, Gertz MA, Banks PM, Pittelkow MR. Transient acantholytic dermatosis associated with lymphomatous angioimmunoblastic lymphadenopathy. Acta Derm Venereol. 1989; 69 (5):445-8
    View PubMed
  933. Tefferi A, Li CY, Phyliky RL. Role of immunotyping in chronic lymphocytosis: review of the natural history of the condition in 145 adult patients. Mayo Clin Proc. 1988 Aug; 63 (8):801-6
    View PubMed
PST-20221417